Modified or targeted release formulations of linaclotide
A stable, delayed release formulation of linaclotide using Ca2+, histidine, and PVA with an enteric coating addresses the issue of excessive upper GI fluid secretion, ensuring effective treatment of gastrointestinal disorders with reduced side effects by targeting the lower GI.
Patent Information
- Application Number
- JP2024140831
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-05-20
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current formulations of linaclotide, used to treat gastrointestinal disorders, result in excessive fluid secretion in the upper GI due to activation of GC-C receptors, leading to adverse events like diarrhea, while degrading before reaching the distal colon, thus necessitating stable, delayed release compositions that target the lower GI for improved efficacy and reduced side effects.
A delayed release composition comprising linaclotide, Ca2+, histidine, and polyvinyl alcohol (PVA) with an enteric coating, using Eudragit® polymers, to ensure stable delivery and release in the lower GI, minimizing upper GI activation and maintaining therapeutic effectiveness.
The composition achieves targeted release of linaclotide in the lower GI, reducing overall fluid secretion and adverse events like diarrhea, while maintaining pain relief and symptom improvement for gastrointestinal disorders.
Smart Images

Figure 2024161048000051 
Figure 2024161048000052 
Figure 2024161048000053
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or a pharma- ceutically acceptable salt thereof, as well as various methods and processes for the preparation and use of said compositions.
[0002] Claiming priority This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 62 / 171,462, filed June 5, 2015, and U.S. Provisional Patent Application No. 62 / 339,462, filed May 20, 2016, the entire contents of which are incorporated herein by reference.
[0003] Sequence Listing This application incorporates by reference in its entirety the Sequence Listing entitled “IW158PCT1_ST25.txt” (4,504 bytes), filed June 1, 2016 and filed electronically herewith. [Background technology]
[0004] 2. Background of the Invention Various formulation techniques have been used to develop delayed release compositions of pharmacoactive agents, including the use of enteric coating or pH-responsive polymers.However, the specific components of these compositions vary greatly and depend greatly on the specific pharmacoactive agent and the desired properties.For example, the formulation must be compatible with the pharmacoactive agent and also provide the necessary dissolution performance and stability properties.
[0005] Nos. 7,304,036 and 7,371,727, incorporated herein by reference, disclose peptides that act as agonists of the guanylate cyclase C (GC-C) receptor for the treatment of gastrointestinal (GI) disorders. One particular peptide disclosed is linaclotide, which consists of the following amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr. Linaclotide has the following chemical structure: [ka]
[0006] Linaclotide is administered orally and is approved by the FDA in the United States for the treatment of irritable bowel syndrome with constipation (IBS-c) and chronic idiopathic constipation (CIC). In humans, linaclotide has been shown to affect GI physiology, including reducing visceral pain, reducing abdominal bloating, and accelerating GI transit, which can lead to increased stool frequency and improved stool consistency. Orally administered linaclotide acts locally by binding to and activating the GC-C receptor on the luminal side of the intestine. The GC-C receptor is a key regulator of intestinal function in mammals and is found throughout the luminal side of the GI tract. The GC-C receptor responds to endogenous hormones, guanylin and uroguanylin, and enterobacterial peptides (ST peptides) from the heat-stable enterotoxin family. When linaclotide binds to the GC-C receptor, there is an intracellular increase in the second messenger cyclic GMP (c-GMP) and an increase in chloride and bicarbonate secretion, resulting in increased interstitial fluid secretion and reduced abdominal pain.
[0007] As approved by the FDA, linaclotide is administered in an oral solid immediate release capsule formulation prepared by filling drug-layered beads into gelatin capsules. Due to the high expression of GC-C receptors throughout the GI tract, linaclotide from immediate release formulations will activate GC-C receptors and start from the upper GI tract, resulting in a significant amount of interstitial fluid in the lower GI tract. To reduce or mitigate this effect, a delayed release composition is needed that targets the release of linaclotide in the distal or lower segments of the gastrointestinal tract. Targeting the lower GI for linaclotide release can help avoid excess fluid secretion while maintaining or improving the effectiveness of linaclotide in treating abdominal and intestinal symptoms of GI disorders.
[0008] It is estimated that 13 million adults in the United States have IBS-c and 35 million adults have CIC. An estimated 15 million adults also suffer from IBS-m. Currently, 6.3 million adults are seeking treatment and are not met by current treatments for IBS-m. Abdominal or visceral pain is the primary symptom reported by patients with IBS, CIC, and other gastrointestinal disorders. As a result, there is a need for a therapy that provides improved visceral pain relief and greater tolerability for adults with IBS-c, IBS-m, and CIC.
[0009] Linaclotide has previously been demonstrated to reduce visceral pain, which is believed to be mediated by increasing cGMP in the GI tract. Animal studies have shown that orally administered linaclotide can treat colonic hypersensitivity and hyperalgesia. However, due to the reducing environment of the intestinal tract, it is known that much of an oral linaclotide dose is degraded before reaching the distal colon. In human volunteers treated with linaclotide, only about 5% of the oral dose is found in the stool. Delayed release ("DR") compositions of linaclotide that target the lower GI can improve the efficacy of linaclotide in relieving pain associated with various GI disorders by allowing for the delivery of higher amounts of linaclotide to the colon. Such DR compositions of linaclotide will have the potential to release linaclotide preferentially (or completely) within the lower GI. As a result, for example, a DR formulation or composition may have a high ability to treat lower GI-related disorders. Furthermore, it may have the potential to result in a lower incidence of adverse events (such as diarrhea) than immediate release dosage forms, for example, by not activating GC-C receptors in the upper GI, thereby causing generalized lower intestinal fluid secretion, while maintaining or even improving the efficacy of linaclotide in treating symptoms of GI disorders such as pain.
[0010] Despite the need for delayed release compositions of linaclotide, difficulties exist in preparing such formulations due to the inherent chemical instability of linaclotide due to moisture-induced degradation reactions such as hydrolysis, deamidation, isomerization, and multimerization. These difficulties can be exacerbated when producing formulations with lower doses of linaclotide. Thus, there is an ongoing need for delayed release compositions that allow for consistent and reliable delivery of linaclotide to targeted regions of the gastrointestinal tract. [Prior art documents] [Patent documents]
[0011] [Patent Document 1] U.S. Patent No. 7,304,036 [Patent Document 2] U.S. Patent No. 7,371,727 Summary of the Invention [Problem to be solved by the invention]
[0012] Summary of the Invention The present invention relates to stable solid oral dosage forms of linaclotide that exhibit delayed release of linaclotide to the lower gastrointestinal tract. Additionally, the present invention provides methods for treating conditions by administering these delayed release compositions. The delayed release compositions of the present invention can be used to treat a variety of conditions, but are particularly suitable for treating gastrointestinal disorders such as irritable bowel syndrome ("IBS") (e.g., IBS with constipation "IBS-c", IBS with diarrhea "IBS-d", or mixed IBS with constipation and diarrhea "IBS-m"), constipation (e.g., chronic idiopathic constipation), colon cancer, diverticulitis, interstitial cystitis, and abdominal or visceral pain.
[0013] Some embodiments provide a method of treating gastrointestinal disorders or pain, comprising administering to a patient in need of treatment a composition disclosed herein. [Means for solving the problem]
[0014] E1. A delayed release composition comprising an enteric coated tablet according to a first aspect of the present invention, the tablet comprising: i. Linaclotide; ii. Ca 2+ ; iii. histidine; and iv. Polyvinyl alcohol (PVA) Including, Linaclotide is present in the composition in an amount of 30 μg to 300 μg; A delayed release composition is provided. E2. The delayed release composition of E1, wherein the linaclotide is present in an amount of 30 μg. E3. The delayed release composition according to E1-E2, wherein the linaclotide is present in an amount of 100 μg. E4. The delayed release composition according to E1-E3, wherein the linaclotide is present in an amount of 300 μg. E5. The delayed release composition according to E1-E4, wherein the tablet comprises at least 1.25% (w / w) PVA. E6. A delayed release composition as described in E1-E4, wherein the tablet comprises at least 1.49% (w / w) PVA. E7. The delayed release composition of any one of E1-E6, wherein the tablet comprises at least 0.44% (w / w) CaCl2. E8. A delayed release composition according to any one of E1-E7, wherein the tablet comprises at least 0.71% (w / w) CaCl2. E9. The delayed release composition of any one of E1-E8, wherein the tablet comprises at least 0.93% (w / w) histidine. E10. The delayed release composition of any one of E1-E9, wherein the tablet comprises at least 1.49% (w / w) histidine. E11. The delayed release composition of any one of E1-E10, wherein the enteric coating comprises a methyl acrylate-methacrylic acid copolymer (e.g., Eudragit®). E12. The delayed release composition of any one of E1-E11, wherein the enteric coating comprises Eudragit® S100, Eudragit® L100, or a Eudragit® S100 / Eudragit® L100 mixture. E13. The delayed release composition of any one of E1-E12, further comprising an enteric coating and a protective polymeric film or subcoating. E14. The delayed release composition of E13, wherein the subcoating comprises Opadry II®. E15. A unit dosage form comprising a delayed release composition according to any one of E1 to E14. E16. A method for producing a composition according to any one of E1 to E15, comprising preparing a linaclotide base, a pregranulation filler, and a placebo base; The linaclotide base, pregranulated filler, and placebo base are blended and compressed into tablets. A method comprising: E17. The method of E16, wherein the pre-granulated filler is prepared via wet granulation and dried prior to blending and compression into tablets. E18. The method of E15 or E16, further comprising applying a subcoat to the tablet. E19. The method of E18, wherein the subcoat comprises Opadry II®. E20. The method of any of E16-E19, further comprising applying an enteric or functional coating to the tablet. E21. The method of E20, wherein the enteric or functional coating comprises Eudragit® S100, Eudragit® L100, or a Eudragit® S100 / Eudragit® L100 mixture. E22. A composition prepared by the method according to any one of E16 to E21. E23. A method for treating a gastrointestinal disorder, comprising administering to a patient in need of treatment a therapeutically effective amount of a composition described in any one of E1-E14 or E22. E24. The method of E23, wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome (IBS), constipation, functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, diverticulitis, visceral pain, abdominal pain, gastroparesis, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, ulcerative colitis, and inflammatory bowel disease. E25. The method of E24, wherein the gastrointestinal disorder is constipation. E26. The method of E25, wherein the constipation is chronic constipation, idiopathic constipation, chronic idiopathic constipation, constipation caused by postoperative ileus, or constipation caused by opiate use. E27. The method of E23, wherein the gastrointestinal disorder is irritable bowel syndrome (IBS). E28. The method of E27, wherein the irritable bowel syndrome is constipation-predominant irritable bowel syndrome (IBS-c), diarrhea-predominant irritable bowel syndrome (IBS-d) or mixed irritable bowel syndrome (IBS-m). E29. The method of E23, wherein the gastrointestinal disorder is diarrhea. E30. The method of E23, wherein the gastrointestinal disorder is gastroparesis. E31. The method of E30, wherein said gastroparesis is idiopathic, diabetic or post-operative gastroparesis. E32. The method of E23, wherein the gastrointestinal disorder is chronic ileus pseudo-obstruction. E33. The method of E23, wherein the gastrointestinal disorder is Crohn's disease. E34. The method of E23, wherein the gastrointestinal disorder is ulcerative colitis. E35. The method of E23, wherein the gastrointestinal disorder is inflammatory bowel disease. E36. The method of E23, wherein the gastrointestinal disorder is visceral pain. E37. The method of E23, wherein the gastrointestinal disorder is diverticulitis. E38. The method of E23, wherein the gastrointestinal disorder is abdominal pain. E39. The method of E23, wherein the gastrointestinal disorder is a cancer selected from colorectal / regionally metastatic colorectal cancer, gastric cancer, intestinal polyps, cancer of the gastrointestinal tract, cancer or precancerous or metastatic growths of epithelial cells or polyps of colorectal tissue. E40. A method for treating or alleviating pain comprising administering to a patient in need thereof a therapeutically effective amount of a composition described in any one of E1-E14 or E22. E41. The method of E40, wherein the pain is selected from visceral pain; diverticulitis pain; pelvic pain; abdominal pain; or pain associated with a gastrointestinal disorder, a sexually transmitted disease, a painful bladder syndrome, or interstitial cystitis. E42. The method of E40, wherein the pain is selected from general abdominal pain, diverticular disease, pain associated with irritable bowel syndrome (IBS), chronic or acute radiation rectal disease (also called radiation proctitis), rectal pain, chronic perianal pain, resolving anorectal pain, anal region pain, chronic anal fissure, postoperative anal region pain, overactive bladder syndrome, stress urinary incontinence, interstitial cystitis, bladder pain syndrome, cancer-related pain, pain associated with gastrointestinal neoplasms, general pelvic pain, endometriosis, testicular pain, chronic prostatitis, prostatic pain, vulvar pain, urethral syndrome, penile pain, perianal pain, and pain associated with ulcerative colitis, ulcerative proctitis, or Crohn's disease. E43. A method for treating overactive bladder syndrome, bladder hypersensitivity, or colitis-induced bladder afferent hyperactivity, comprising administering to a patient in need of treatment a therapeutically effective amount of a composition described in any one of E1-E14 or E22. E44. A method of increasing intestinal motility in a patient, comprising administering to the patient a composition described in any one of E1-E14 or E22. E45. A method for increasing guanylate cyclase C (GC-C) receptor activity in a biological sample or organism, comprising contacting the biological sample or organism with a composition described in any one of E1-E14 or E22. A method for producing a composition according to any one of E46.E1 to E14, comprising the steps of: i. preparing an aqueous solution containing linaclotide, or a pharma- ceutical acceptable salt thereof; and ii. applying the aqueous solution to a pharma- ceutical acceptable carrier. A method comprising: E47. A composition prepared by the method described in E46. [Brief description of the drawings]
[0015] [Figure 1] 1 shows the release profile at various pH values for a delayed release tablet composition containing 100 μg of linaclotide. [Diagram 2] Bladder afferent and compliance responses to ramp distention in CVH mice treated with vehicle (black, N=6) or linaclotide (grey, N=13) by oral gavage once daily for 14 days are shown. [Diagram 3] Figure 3A shows bladder afferent responses to carbachol (1 μM) p≦0.001 in CVH mice treated with vehicle (black, n=7) or linaclotide (gray, n=7) by oral gavage once a day (2-way ANOVA Bonferroni multiple comparison test). Figure 3B shows bladder afferent responses to capsaicin (10 μM) p≦0.01 in CVH mice treated with vehicle (black, n=7) or linaclotide (gray, n=7) by oral gavage once a day (2-way ANOVA Bonferroni multiple comparison test). FIG. 3C shows bladder afferent responses to αβMe-ATP (30 μM) p≦0.001 in CVH mice treated with vehicle (black, n=7) or linaclotide (gray, n=7) by oral gavage once daily (2-way ANOVA Bonferroni multiple comparison test). [Figure 4] Figure 4A shows electrophysiological properties of retrogradely traced bladder thoracic-lumbar (TL) DRG neurons from CVH mice treated with vehicle (n=27) or linaclotide (n=25) by oral gavage once daily, where linaclotide significantly increases the rheobase compared to the vehicle group (p=0.02). Figure 4B shows electrophysiological properties of retrogradely traced bladder thoracic-lumbar (TL) DRG neurons from CVH mice treated with vehicle (n=27) or linaclotide (n=25) by oral gavage once daily, where linaclotide significantly reduces the number of action potentials at 2× the rheobase compared to the vehicle group (p=0.02). FIG 4C shows electrophysiological properties of retrogradely traced bladder thoracic-lumbar (TL) DRG neurons from CVH mice treated with once-daily oral gavage of vehicle (n=27) or linaclotide (n=25), with linaclotide having no effect on resting membrane potential compared to mice receiving vehicle gavage. [Diagram 5]Figure 1 shows the rheobase of retrogradely traced bladder thoracic-lumbar (TL) DRG neurons from healthy mice (n=19), CVH mice (n=22), and CVH mice treated with vehicle (n=27) or linaclotide (n=25) by oral gavage once daily. The rheobase was significantly reduced in CVH mice, and this effect was reversed by oral gavage of linaclotide (p≦0.05, 1-way ANOVA). [Figure 6] 1 shows stability studies over time for a representative formulation of linaclotide and percent / negative loss of linaclotide. [Figure 7] 1 shows stability studies over time for a representative formulation of linaclotide and the percent increase in the α-ketone degradation product of linaclotide ("Cys1-α-ketone"); [Figure 8] 1 shows stability studies over time for a representative formulation of linaclotide and the percent increase in the immdidazolidinone degradation product of linaclotide ("Cys1-IMD"). [Figure 9] 1 shows stability studies over time and percent / negative loss of linaclotide for formulations 1 and 64B of linaclotide. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] Detailed Description of the Invention Provided herein are delayed release oral dosage forms (collectively, "DR") of linaclotide. To date, the only approved formulations of linaclotide are capsules exhibiting immediate release ("IR"). These IR dosage forms release most or all of the linaclotide contained therein within the upper GI. This in turn causes GC-C receptor activation and fluid secretion in both the upper GI and, to a lesser extent, the lower GI. The difference in upper and lower GI activation and fluid secretion by IR dosage forms is due, in part, to the fact that linaclotide (once released from the dosage form) undergoes proteolytic digestion and in particular loses some or all of its ability to activate GC-C receptors by the time it reaches the lower GI (e.g., the ileum, terminal ileum, ileocecal valve, or colon).
[0017] The DR dosage form described herein releases most or all of the linaclotide contained therein, for example in the lower GI closest to the ileocecal valve or in the colon (with little or no release in the stomach, duodenum and / or jejunum).Thus, the dosage form of the present invention has the ability to achieve lower overall fluid secretion in the upper GI than IR dosage forms, while improving or even maintaining its excellent efficacy for treating IBS-c, CIC, and modulating gastrointestinal pain sensory signaling.Since IBS patients report left lower abdominal pain as a symptom of their disorder, it is believed that IBS pain originates from the colon.Furthermore, it is believed that DR dosage forms are ideally suited for treating lower GI-related diseases and disorders. Because DR dosage forms do not release any (or only a small percentage) of their linaclotide in the stomach and upper GI (which can cause rapid digestion of linaclotide in the intestine), some preferred embodiments of DR dosage forms incorporate lower doses of linaclotide (compared to the amount in approved IR forms) while maintaining the same efficacy levels as IR in treating the symptoms of IBS-c and CIC.
[0018] In general, guanylate cyclase C (GC-C) receptors are transmembrane receptors located on the apical membrane side of epithelial cells in the stomach and intestine. The receptor has an extracellular ligand-binding domain, a single transmembrane region, and a C-terminal guanylyl cyclase domain. Upon ligand binding to the extracellular domain of GC-C, the intracellular catalytic domain catalyzes the production of cGMP from GTP. In vivo, this increase in intracellular cGMP initiates a series of events that lead to increased secretion of chloride and bicarbonate into the intestinal lumen, increased luminal pH, reduced luminal sodium absorption, increased fluid secretion, and accelerated intestinal transit. cGMP is secreted bidirectionally from the epithelium into the submucosa and lumen. Normally, the pH of the GI tract gradually increases from the stomach (pH 1.5-3) to the terminal ileum (pH 7-8) before decreasing to pH 5.5-7.0 in the colon.
[0019] Linaclotide binds to the intestinal GC-C receptor, a regulator of fluid and electrolyte balance in the intestine. Linaclotide binds to the intestinal GC-C receptor, a regulator of fluid and electrolyte balance in the intestine. 10 Thr 11 Gly 12 Cys 13 Tyr 14 Linaclotide is a peptide consisting of Cys1 and Cys6, Cys2 and Cys3, and Cys4 and Cys5. Any desired form of linaclotide can be used in the composition, for example, any pharma- ceutically acceptable salt or hydrate of the peptide, any isolated and / or purified form thereof, or any disulfide form thereof. Linaclotide is a peptide consisting of Cys1 and Cys6, Cys2 and Cys3, and Cys4 and Cys5. 10 , and Cys5 and Cys 13 It has a disulfide bond between them.
[0020] A variety of disorders can be treated with DR compositions containing linaclotide. In various embodiments, the patient suffers from a gastrointestinal disorder; the patient may suffer from gastrointestinal motility disorder, chronic intestinal pseudo-obstruction, pseudo-colonic obstruction, inflammatory bowel disease, Crohn's disease, duodenogastric reflux, dyspepsia, functional dyspepsia, non-ulcer dyspepsia, functional gastrointestinal disorder, functional heartburn, gastroesophageal reflux disease (GERD), gastroparesis, irritable bowel syndrome (e.g., diarrhea-predominant irritable bowel syndrome (IBS-d), constipation-predominant irritable bowel syndrome (IBS-c) and / or alternating or mixed irritable bowel syndrome (IBS-c)). The patient suffers from a disorder selected from the group consisting of combined irritable bowel syndrome (IBS-m), postoperative ileus, ulcerative colitis, chronic constipation, constipation, interstitial cystitis, prostatitis, testicular pain, painful bladder syndrome, endometriosis, vulvodynia, rectal pain, diverticular disease or diverticular pain, pain associated with GI disorders, and constipation-related disorders and conditions (e.g., constipation associated with the use of opiate analgesics, postoperative constipation, and constipation associated with neurological disorders as well as other conditions and disorders described herein). The patient may be diagnosed with a functional gastrointestinal disorder (e.g., IBS-c) according to the Rome Criteria (e.g., Rome II).
[0021] In some embodiments, the DR composition comprises an enteric coated tablet containing an immediate release tablet core and a unit dose of linaclotide that dissolves only under the pH conditions of the distal segment of the intestine. In some embodiments, the enteric or functional coating is selected from methyl acrylate-methacrylic acid copolymer (e.g., Eudragit®); cellulose acetate succinate (CAS); hydroxypropyl methylcellulose phthalate (HPMCP); PVA; PVP; PVP-LP, hydroxypropyl methylcellulose acetate succinate (HPMCAS); polyvinyl acetate phthalate (PVAP); methyl methacrylate-methacrylic acid copolymer; sodium alginate and stearic acid; guar gum; and carbomer. In a further embodiment, the enteric coating is selected from Eudragit® FS30D, PlasAcryl®, Eudragit® S100, Eudragit® L100, Eudragit® L100-55, Eudragit® L30D-55, Eudragit® S, Eudragit® RL30D, Eudragit® RS30D, Eudragit® RS, Eudragit® EC, or mixtures thereof.
[0022] The delayed release composition may contain any effective amount of linaclotide. In some embodiments, for example, the composition contains 0.05 μg to 6 mg of linaclotide. In some embodiments, for example, the composition contains 1 μg to 2 mg of linaclotide. In some embodiments, for example, the composition contains 25 μg to 2 mg of linaclotide, for example, 50 μg to 1 mg of linaclotide. In some embodiments, for example, the composition contains 0.1 μg to 90 μg of linaclotide. In some embodiments, for example, the composition contains 0.1 μg to 45 μg of linaclotide. In some embodiments, for example, the composition contains 0.1 μg to 25 μg of linaclotide. In some embodiments, for example, the composition contains 36 μg to 290 μg of linaclotide. In some embodiments, the composition is administered in the amount of 0.05 μg, 0.1 μg, 0.15 μg, 0.25 μg, 0.5 μg, 0.75 μg, 1 μg, 1.5 μg, 2 μg, 2.5 μg, 3 μg, 3.5 μg, 4 μg, 4.5 μg, 5 μg, 7.5 μg, 9 μg, 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg , 36μg, 40μg, 45μg, 50μg, 60μg, 72μg, 75μg, 90μg, 100μg, 145μg, 150μg, 200μg, 250μg g, 290μg, 300μg, 350μg, 400μg, 450μg, 500μg, 550μg, 579μg, 600μg, 650μg, 700μg, 75 In some embodiments, the composition comprises 0 μg, 800 μg, 850 μg, 900 μg, 950 μg, or 1 mg of linaclotide. In some embodiments, the composition comprises 100 μg to 600 μg of linaclotide. In some embodiments, the composition comprises 30 μg, 50 μg, 75 μg, 100 μg, 150 μg, 290 μg, 300 μg, 400 μg, 500 μg, or 600 μg of linaclotide. In some embodiments, the composition comprises 9 μg, 10 μg, 15 μg, 36 μg, 72 μg, 75 μg, 145 μg, 290 μg, 579 μg, or 600 μg of linaclotide.
[0023] In some embodiments, the composition comprises 30 μg of linaclotide. In some embodiments, the composition comprises 50 μg of linaclotide. In some embodiments, the composition comprises 100 μg of linaclotide. In some embodiments, the composition comprises 145 μg of linaclotide. In some embodiments, the composition comprises 300 μg of linaclotide.
[0024] In some embodiments, it has been found that the stability of delayed release compositions of linaclotide can be enhanced or improved by including in the composition an appropriate amount of a sterically hindered primary amine (e.g., amino acid) component, a cation (e.g., metal cation) component, and / or a polymer component. These components enhance or improve the stability of delayed release compositions of linaclotide, for example, by preventing, reducing, and / or reducing degradation of linaclotide in the composition (e.g., due to moisture-induced decomposition reactions, e.g., hydrolysis, deamidation, isomerization, and / or multimerization). For example, in some embodiments, the composition can include an appropriate amount of a cation (e.g., Mg 2+ , Ca 2+ , Zn 2+ ) has been found to increase the stability of the composition against oxidative degradation of linaclotide. Further, in some embodiments, the inclusion of a suitable amount of a sterically hindered primary amine in the form of, for example, an amino acid (e.g., histidine) in the composition has been found to increase the stability of the composition against, for example, the nucleophilic addition of formaldehyde or a formaldehyde equivalent to the N-terminus of linaclotide, e.g., by acting as a scavenger and / or buffering the composition ... 2+ ), the hydrolysis products of linaclotide and formaldehyde (Cys 1It has been found that inclusion of a suitable amount of a polymer (e.g., polyvinylpyrrolidone or polyvinyl alcohol) in the delayed release composition enhances the stability of the composition against the formation of linaclotide-IMD) products. It has also been found that in some embodiments, the inclusion of a suitable amount of a polymer (e.g., polyvinylpyrrolidone or polyvinyl alcohol) in the delayed release composition enhances the stability of the composition, for example, by reducing the mobility and / or reactivity of linaclotide within the composition, for example, by forming a complex or matrix (e.g., a glassy and / or rigid matrix) with linaclotide (e.g., a vitrification reaction), by preventing or reducing hydrogen bond formation between linaclotide and water molecules, and / or by enhancing the three-dimensional structural integrity of linaclotide.
[0025] In this regard, in some embodiments, it has been found that combining linaclotide in a delayed release pharmaceutical composition with specific concentrations or molar ratios of cations and sterically hindered primary amines results in a synergistic enhancement or improvement in the stability of linaclotide in the composition, for example, compared to a similar composition that does not contain the cations and / or sterically hindered primary amines and / or the same concentrations of these components. In some embodiments, the composition can include any stabilizing amount of a sterically hindered primary amine component. In other embodiments, the composition has a molar ratio of sterically hindered primary amine to linaclotide of 400:1 to 1:1. In further embodiments, the composition has a molar ratio of sterically hindered primary amine to linaclotide of 200:1 to 50:1. In other embodiments, the composition can have a molar ratio of sterically hindered primary amine (e.g., amino acid) to linaclotide of 100:1 to 1:100. In some embodiments, the composition has a molar ratio of sterically hindered primary amine to linaclotide of 100:1 to 1:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of 90:1 to 2:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of 80:1 to 5:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of 70:1 to 10:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of 60:1 to 20:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of 50:1 to 30:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of 40:1 to 20:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of 100:1 to 20:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of 100:1 to 25:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amine to linaclotide of 100:1 to 30:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amine to linaclotide of 100:1 to 40:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amine to linaclotide of 100:1 to 50:1.In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of 100:1 to 60:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of 100:1 to 70:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of at least 5:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of at least 10:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of at least 20:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of at least 25:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of at least 30:1. In some embodiments, the composition has a molar ratio of sterically hindered primary amines to linaclotide of at least 40:1.
[0026] Suitable sterically hindered primary amines for inclusion in the delayed release composition include, for example, naturally occurring amino acids (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, meglumine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine), synthetic amino acids (e.g., lanthionine, theanine or 1-aminocyclohexane), amino sugars (e.g., chitosan or glucosamine), or combinations or mixtures thereof. In some embodiments, the composition comprises an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or mixtures thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, asparagine, glutamine, glutamic acid, histidine, cysteine, alanine, serine, threonine, tyrosine, proline, tryptophan, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, methionine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, methion ... methionine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, methionine, or a mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, or a mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, or a mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, alanine, or a mixture thereof. In some embodiments, the composition comprises a leucine. In some embodiments, the composition comprises an isoleucine.In some embodiments, the composition comprises methionine. In some embodiments, the composition comprises alanine. In some embodiments, the composition comprises histidine.
[0027] The delayed release composition can include any stabilizing amount of cation (e.g., metal cation). In some embodiments, the composition has a molar ratio of cation to linaclotide of 300:1 to 1:1. In further embodiments, the composition has a molar ratio of cation to linaclotide of 250:1 to 30:1. In other embodiments, the composition can have a molar ratio of cation to linaclotide of 100:1 to 1:100. In some embodiments, the composition has a molar ratio of cation to linaclotide of 100:1 to 1:1. In some embodiments, the composition has a molar ratio of cation to linaclotide of 90:1 to 2:1. In some embodiments, the composition has a molar ratio of cation to linaclotide of 80:1 to 5:1. In some embodiments, the composition has a molar ratio of cation to linaclotide of 70:1 to 10:1. In some embodiments, the composition has a molar ratio of cation to linaclotide of 60:1 to 20:1. In some embodiments, the composition has a molar ratio of cations to linaclotide of 50:1 to 30:1. In some embodiments, the composition has a molar ratio of cations to linaclotide of 40:1 to 20:1. In some embodiments, the composition has a molar ratio of cations to linaclotide of 100:1 to 20:1. In some embodiments, the composition has a molar ratio of cations to linaclotide of 100:1 to 25:1. In some embodiments, the composition has a molar ratio of cations to linaclotide of 100:1 to 30:1. In some embodiments, the composition has a molar ratio of cations to linaclotide of 100:1 to 40:1. In some embodiments, the composition has a molar ratio of cations to linaclotide of 100:1 to 50:1. In some embodiments, the composition has a molar ratio of cations to linaclotide of 100:1 to 60:1. In some embodiments, the composition has a molar ratio of cations to linaclotide of 100:1 to 70:1. In some embodiments, the composition has a molar ratio of cation to linaclotide of at least 5:1. In some embodiments, the composition has a molar ratio of cation to linaclotide of at least 10:1. In some embodiments, the composition has a molar ratio of cation to linaclotide of at least 20:1.In some embodiments, the composition has a molar ratio of cation to linaclotide of at least 25:1. In some embodiments, the composition has a molar ratio of cation to linaclotide of at least 30:1. In some embodiments, the composition has a molar ratio of cation to linaclotide of at least 40:1. In some embodiments, the composition has a molar ratio of cation to linaclotide of at least 60:1.
[0028] Any suitable cation(s) can be included in the composition, for example, any suitable metal cation or organic cation. In some embodiments, the composition comprises a metal cation selected from calcium, potassium, magnesium, zinc, aluminum, iron, tin, manganese, chromium, cobalt, nickel, barium, sodium, or a combination or mixture thereof. In some embodiments, the composition comprises a metal cation selected from calcium, potassium, magnesium, zinc, aluminum, manganese, chromium, cobalt, nickel, barium, sodium, or a combination or mixture thereof. In some embodiments, the composition comprises a metal cation selected from aluminum, calcium, potassium, sodium, magnesium, manganese, zinc, or a combination or mixture thereof. In some embodiments, the composition comprises a metal cation selected from calcium, magnesium, manganese, zinc, or a combination or mixture thereof. In some embodiments, the composition comprises a divalent metal cation. In some embodiments, the composition comprises a divalent metal cation, such as Al. 3+ , Ca 2+ , Mg 2+ , Zn 2+ , Mn 2+ or a combination or mixture thereof. In some embodiments, the composition comprises a divalent metal cation selected from Mg 2+ In some embodiments, the composition comprises Ca 2+ In some embodiments, the composition comprises Zn 2+ In some embodiments, the composition comprises aluminum.
[0029] Furthermore, the metal cation can be added to the composition in any suitable form, for example, in the form of any pharma- ceutically acceptable salt with any suitable counterion. Suitable metal salts include, for example, calcium chloride, calcium carbonate, calcium acetate, magnesium chloride, magnesium acetate, zinc acetate, zinc chloride, or mixtures thereof. In some embodiments, the composition comprises calcium chloride, magnesium chloride, zinc acetate, or any combination or mixture thereof. In some embodiments, the composition comprises calcium chloride. In some embodiments, the composition comprises magnesium chloride. In some embodiments, the composition comprises zinc acetate. Suitable organic cations include, for example, ammonium hydroxide, D-arginine, L-arginine, t-butylamine, calcium acetate hydrate, calcium carbonate, DL-calcium malate, calcium hydroxide, choline, ethanolamine, ethylenediamine, glycine, L-histidine, L-lysine, magnesium hydroxide, N-methyl-D-glucamine, L-ornithine hydrochloride, potassium hydroxide, procaine hydrochloride, L-proline, pyridoxine, L-serine, sodium hydroxide, DL-tryptophan, tromethamine, L-tyrosine, L-valine, carnitine, taurine, creatine malate, arginine alpha ketoglutarate, ornithine alpha ketoglutarate, spermine acetate, spermine chloride, or combinations or mixtures thereof. In some embodiments, the organic cation is selected from the group consisting of N-methyl D-glucamine, choline, arginine, lysine, procaine, tromethamine (TRIS), spermine, N-methyl-morpholine, glucosamine, N,N-bis(2-hydroxyethyl)glycine, diazabicycloundecene, creatine, arginine ethyl ester, amantadine, rimantadine, ornithine, taurine, citrulline, or combinations or mixtures thereof.
[0030] The composition can contain any stabilizing amount of polymer. In some embodiments, the composition comprises 1-25 wt% of polymer based on the total weight of the composition. In some embodiments, the composition comprises 1-10 wt% of polymer based on the total weight of the composition.
[0031] In some embodiments, the composition comprises 2-4 wt.% of the polymer, based on the total weight of the composition. In some embodiments, the composition comprises 0.1-75 wt.% of the polymer. In some embodiments, the composition comprises 0.1-55 wt.% of the polymer. In some embodiments, the composition comprises 0.1-35 wt.% of the polymer. In some embodiments, the composition comprises 0.1-30 wt.% of the polymer. In some embodiments, the composition comprises 0.1-25 wt.% of the polymer. In some embodiments, the composition comprises 1-25 wt.% of the polymer. In some embodiments, the composition comprises 5-25 wt.% of the polymer. In some embodiments, the composition comprises 10-25 wt.% of the polymer. In some embodiments, the composition comprises 15-25 wt.% of the polymer. In some embodiments, the composition comprises 0.1-22 wt.% of the polymer. In some embodiments, the composition comprises 1-22 wt.% of the polymer. In some embodiments, the composition comprises 5-22 wt.% of the polymer. In some embodiments, the composition comprises 10-22 wt.% of the polymer. In some embodiments, the composition comprises 0.1-20 wt.% of the polymer. In some embodiments, the composition comprises 1-20 wt.% of the polymer. In some embodiments, the composition comprises 5-20 wt.% of the polymer. In some embodiments, the composition comprises 10-20 wt.% of the polymer. In some embodiments, the composition comprises 0.01-15 wt.% of the polymer. In some embodiments, the composition comprises 0.01-10 wt.% of the polymer. In some embodiments, the composition comprises 0.01-5 wt.% of the polymer.In some embodiments, the composition comprises 0.1-95 wt.%, e.g., 5-95 wt.%, 15-95 wt.%, 25-95 wt.%, 35-95 wt.%, 45-95 wt.%, 0.1-85 wt.%, 1-85 wt.%, 5-85 wt.%, 15-85 wt.%, 25-85 wt.%, 35-85 wt.%, 0.1-80 wt.%, 1-80 wt.%, 5-80 wt.%, 15-80 wt.%, 25-80 wt.%, 35-80 wt.%, 45-95 ... wt.%, 0.1-75wt.%, 1-75wt.%, 5-75wt.%, 15-75wt.%, 25-75wt.%, 35-75wt.%, 0.1-65wt.%, 1-65wt.%, 5-65wt.%, 15-65wt.%, 25-65wt.%, 35-65wt.%, 0.1-60wt.%, 1-60wt.%, 5-60wt.%, 15-60wt.%, 25-60wt.%, or 35-60wt.% polymer.
[0032] In some embodiments, the polymer acts as a stabilizer, protective coating, or film-forming agent in the delayed release composition. In some embodiments, the delayed release composition has a molar ratio of polymer (e.g., PVP or PVA) to linaclotide of 80:1 to 300:1, for example, between 100:200:1, 110:1 to 190:1, or even 120:1 to 180:1. In some embodiments, the delayed release composition has a molar ratio of polymer (e.g., PVP or PVA) to linaclotide of greater than about 80:1, for example, greater than about 100:1, or even greater than about 120:1. In some embodiments, the delayed release composition has a weight ratio of polymer (e.g., PVP or PVA) to linaclotide of 10:1 to 300:1, for example, 80:1 to 200:1, 100:1 to 180:1, or even 110:1 to 150:1. In some embodiments, the delayed release composition has a weight ratio of polymer (e.g., PVP or PVA) to linaclotide of 100:1 to 500:1, such as 200:1 to 400:1, 250:1 to 350:1, or even 300:1 to 350:1.
[0033] Suitable polymers for inclusion in the delayed release composition include, for example, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), polyvinyl alcohol low peroxide (PVA-LP), hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose, etc. The polymer may be selected from the group consisting of cellulose (HPC), methylcellulose, methacrylic acid polymers, cyclodextrin, dextrin, dextran, polyacrylic acid, chitosan, guar gum, xanthan gum, polyethylene oxide (e.g., polyethylene polypropylene oxide), poly(sodium vinyl sulfonate), polyethylene glycol, poly(arginine), polycarbophil, polyvinylpyrrolidone-co-vinyl acetate, poloxamer (e.g., Pluronic® products available from BASF), alginate, trehalose, sucrose, inulin, or combinations or mixtures thereof. In some embodiments, the composition comprises a polymer selected from PVP, PVA, methacrylic acid polymers, cyclodextrin, dextran, polyacrylic acid, chitosan, guar gum, xanthan gum, polyethylene oxide, polyethylene glycol, poly(arginine), polycarbophil, polyvinylpyrrolidone-co-vinyl acetate, poloxamer, or combinations or mixtures thereof. In some embodiments, the composition comprises PVP, PVA, polyethylene oxide, or mixtures thereof. In some embodiments, the composition comprises PVP, PVA, or a mixture thereof. In some embodiments, the composition comprises PVP. In some embodiments, the composition comprises PVA.
[0034] In some embodiments, the delayed release composition comprises two or more stabilizers. For example, the composition can comprise a stabilizing amount of a polymer and a stabilizing amount of a sterically hindered primary amine. In addition, the composition can comprise a stabilizing amount of a polymer and a stabilizing amount of a cation (e.g., a metal cation). In addition, the composition can comprise a stabilizing amount of a sterically hindered primary amine and a stabilizing amount of a cation (e.g., a metal cation). In some embodiments, the composition comprises a stabilizing amount of a polymer, a stabilizing amount of a sterically hindered primary amine, and a stabilizing amount of a cation (e.g., a metal cation).
[0035] In some embodiments, the delayed release composition comprises a stabilizing amount of PVP and a stabilizing amount of an amino acid selected from histidine, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or a mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or a mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of leucine, isoleucine, methionine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of histidine.
[0036] In some embodiments, the delayed release composition comprises a stabilizing amount of PVA and a stabilizing amount of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or a mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or a mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of leucine, isoleucine, methionine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of leucine.
[0037] In some embodiments, the delayed release composition comprises a stabilizing amount of PVP and a stabilizing amount of a cation (e.g., a metal cation). In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of a divalent metal cation. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of Mg. 2+ , Ca 2+ , Zn 2+ or a salt thereof, or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of Ca 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of Mg. 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of Zn 2+ or a salt thereof.
[0038] In some embodiments, the delayed release composition comprises a stabilizing amount of PVA and a stabilizing amount of a cation (e.g., a metal cation). In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of a divalent metal cation. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of Mg. 2+ , Ca 2+ , Zn 2+ or a salt thereof, or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of Ca 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of Mg. 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of Zn 2+ or a salt thereof.
[0039] In some embodiments, the delayed release composition comprises a stabilizing amount of an amino acid selected from leucine, isoleucine, methionine, alanine; and Mg. 2+ , Ca 2+ , Zn 2+or a salt thereof, or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of an amino acid selected from leucine, and isoleucine; and Mg 2+ , Ca 2+ or a salt thereof, or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of an amino acid selected from leucine or methionine; and Ca 2+ , Zn 2+ or a salt thereof, or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of leucine and a stabilizing amount of Ca. 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of a cation and a stabilizing amount of a sterically hindered primary amine. In some embodiments, the composition comprises a cation and a sterically hindered primary amine in a ratio of at least 1.5:1, e.g., at least 2:1, at least 2.5:1, at least 3:1, at least 4:1, or even at least 5:1 cation:sterically hindered primary amine (e.g., Ca 2+ :leucine) molar ratio (e.g., 1.5:1-5 :1, for example, a molar ratio of 2:1 to 4:1.
[0040] In some embodiments, the delayed release composition comprises: (i) a stabilizing amount of PVP or PVA; (ii) a stabilizing amount of leucine, isoleucine, methionine, alanine; and (iii) a stabilizing amount of Mg. 2+ , Ca 2+ , Zn 2+ or a salt thereof, or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of a metal cation. In some embodiments, the composition comprises a stabilizing amount of PVA, a stabilizing amount of histidine, and a stabilizing amount of Ca. 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of Mg. 2+or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of Zn. 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA, a stabilizing amount of leucine, and a stabilizing amount of Ca. 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA, a stabilizing amount of leucine, and a stabilizing amount of Mg. 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA, a stabilizing amount of leucine, and a stabilizing amount of Zn. 2+ or a salt thereof.
[0041] In some embodiments, the composition comprises (i) 0.1-30 wt.% polymer, (ii) a sterically hindered primary amine (e.g., an amino acid) in a molar ratio of primary amine to linaclotide of 100:1 to 10:1, and (iii) a cation (e.g., a metal cation) in a molar ratio of cation to linaclotide of 100:1 to 40:1. In some embodiments, the composition comprises (i) 5-25 wt.% polymer, (ii) a sterically hindered primary amine (e.g., an amino acid) in a molar ratio of primary amine to linaclotide of 100:1 to 30:1 (e.g., 60:1 to 30:1 or even 50:1 to 30:1); and (iii) a cation (e.g., a metal cation) in a molar ratio of cation to linaclotide of 100:1 to 60:1. In some embodiments, the composition comprises: (i) 0.1-30 wt.% of a polymer selected from PVP and PVA; (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine, in a molar ratio of amino acid to linaclotide of 100:1 to 10:1; and (iii) a molar ratio of cation to linaclotide of 100:1 to 40:1, Ca 2+ , Mg 2+ , and Zn 2+In some embodiments, the composition comprises (i) 5-25 wt.% of a polymer selected from PVP and PVA, (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine, in a molar ratio of amino acid to linaclotide of 100:1 to 30:1 (e.g., 60:1 to 30:1), and (iii) a metal cation selected from Ca, CaH, CaH+ ... 2+ , Mg 2+ , and Zn 2+ In some embodiments, the composition comprises a metal cation selected from: (i) 0.1-30 wt.% (e.g., 5-25 wt.%) PVP or PVA, (ii) leucine in a molar ratio of 100:1-30:1 (e.g., 60:1-30:1 or even 50:1-30:1) leucine to linaclotide, and (iii) Ca in a molar ratio of 100:1-60:1. 2+ Molar ratio of Ca to linaclotide 2+ Includes.
[0042] In some embodiments, the composition comprises (i) 45-99 wt.% polymer, (ii) sterically hindered primary amines (e.g., amino acids) in a molar ratio of primary amines to linaclotide of 100:1 to 10:1, and (iii) cations (e.g., metal cations) in a molar ratio of cations to linaclotide of 100:1 to 40:1. In some embodiments, the composition comprises (i) 45-70 wt.% polymer, (ii) sterically hindered primary amines (e.g., amino acids) in a molar ratio of primary amines to linaclotide of 100:1 to 30:1 (e.g., 60:1 to 30:1 or even 50:1 to 30:1), and (iii) cations (e.g., metal cations) in a molar ratio of cations to linaclotide of 100:1 to 60:1. In some embodiments, the composition comprises: (i) 45-99 wt.% of a polymer selected from PVP and PVA; (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine, in a molar ratio of amino acid to linaclotide of 100:1 to 10:1; and (iii) a molar ratio of cation to linaclotide of 100:1 to 40:1, Ca 2+ , Mg 2+ , and Zn 2+In some embodiments, the composition comprises (i) 45-70 wt.% of a polymer selected from PVP and PVA, (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine, in a molar ratio of amino acid to linaclotide of 100:1 to 30:1 (e.g., 60:1 to 30:1), and (iii) a metal cation selected from Ca, CaH, CaH+ ... 2+ , Mg 2+ , and Zn 2+ In some embodiments, the composition comprises a metal cation selected from: (i) 45-99 wt.% (e.g., 45-70 wt.%) PVP or PVA, (ii) leucine in a molar ratio of 100:1 to 30:1 (e.g., 60:1 to 30:1 or even 50:1 to 30:1) leucine to linaclotide, and (iii) Ca in a molar ratio of 100:1 to 60:1. 2+ Molar ratio of Ca to linaclotide 2+ Includes.
[0043] The delayed release composition (e.g., delayed release tablet) may contain any one or more fillers. Suitable fillers include, but are not limited to, starch, calcium carbonate, calcium sulfate, hydroxypropylmethylcellulose, fructose, methylcellulose, dextrates, dextrose, dextran, lactitol, maltose, sucrose, sorbitol, isomalt, pregelatinized starch, dicalcium phosphate, microcrystalline cellulose, mannitol, gelatin, trehalose, erythritol, maltitol, lactose, glucose, or combinations or mixtures thereof. In some embodiments, the filler is isomalt. In some embodiments, the filler is gelatin. In some embodiments, the filler is mannitol. In some embodiments, the filler is pregelatinized starch. In some embodiments, the filler is microcrystalline cellulose.
[0044] A delayed release composition (e.g., a delayed release tablet) can include any suitable concentration of filler. In some embodiments, for example, the composition includes one or more fillers at a concentration of 0.1-99 wt.% based on the total weight of the composition. In some embodiments, for example, the composition includes one or more fillers at a concentration of 1-95 wt.% of the filler(s) based on the total weight of the composition. In some embodiments, for example, the composition includes one or more fillers at a concentration of 10-90 wt.% of the filler(s) based on the total weight of the composition. In some embodiments, for example, the composition includes one or more fillers at a concentration of 20-90 wt.% of the filler(s) based on the total weight of the composition. In some embodiments, for example, the composition includes one or more fillers at a concentration of 25-85 wt.% of the filler(s) based on the total weight of the composition. In some embodiments, for example, the composition includes one or more fillers at a concentration of 30-80 wt.% of the filler(s) based on the total weight of the composition. In some embodiments, for example, the composition comprises one or more fillers at a concentration of 40-70 wt.% of the filler(s) relative to the total weight of the composition. In some embodiments, for example, the composition comprises one or more fillers at a concentration of 10-60 wt.% of the filler(s) relative to the total weight of the composition. In some embodiments, for example, the composition comprises one or more fillers at a concentration of 20-50 wt.% of the filler(s) relative to the total weight of the composition. In some embodiments, the composition comprises one or more fillers at a concentration of at least 20 wt.%, for example at least 40 wt.%, at least 60 wt.%, at least 70 wt.%, at least 80 wt.%, or at least 90 wt.%, relative to the total weight of the composition.
[0045] In some embodiments, the delayed release composition (e.g., delayed release film) comprises one or more plasticizers. Suitable plasticizers include, but are not limited to, polyethylene glycol, propylene glycol, glycerin, glycerol, monoacetin, diacetin, triacetin, dimethyl phthalate, diethyl phthalate, dibutyl phthalate, dibutyl sebacate, triethyl titrate, tributyl citrate, triethyl citrate, acetyl triethyl citrate, castor oil, acetylated monoglycerides, sorbitol, or combinations thereof. In an exemplary embodiment, the concentration of the plasticizer in the formulation may be about 0 to about 30 wt.%, for example, about 1 to about 20 wt.%, about 0 to about 10 wt.%, about 1 to about 5 wt.%, or even 0 to about 4 wt.%.
[0046] In some embodiments, the delayed release composition comprises a film-forming agent, a water-soluble polymer, a pH-sensitive polymer, a biodegradable polymer, or a combination thereof.Water-soluble, pH-sensitive, or biodegradable polymers that can be used in the orally dissolving formulation of the present invention include, but are not limited to, cellulose derivatives, synthetic polymer polyacrylates, and natural gums.For example, water-soluble polymers that can be used in the orally dissolving formulation of the present invention include, but are not limited to, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate butyrate, amylose, dextran, casein, pullulan, gelatin, pectin, agar, carrageenan, xanthan gum, tragacanth, guar gum, acacia gum, gum arabic, polyethylene glycol, polyethylene oxide, polyvinylpyrrolidone, polyvinyl alcohol, cyclodextrin, carboxyvinyl polymer, sodium alginate, polyacrylic acid, methyl methacrylate, or mixtures thereof. In a typical embodiment, the concentration of the water-soluble polymer in the formulation can be about 20% to about 90% by weight, preferably about 40% to about 80% by weight.
[0047] In some embodiments, the pH sensitive polymer is Eudagrit® L100, which has a threshold pH of 6.0. In some embodiments, the pH sensitive polymer is Eudagrit® S100, which has a threshold pH of 7.0. In some embodiments, the pH sensitive polymer is Eudagrit® L-30D, which has a threshold pH of 5.6. In some embodiments, the pH sensitive polymer is Eudagrit® FS 30D, which has a threshold pH of 6.8. In some embodiments, the pH sensitive polymer is Eudagrit® L100-55, which has a threshold pH of 5.5. In some embodiments, the pH sensitive polymer is polyvinyl acetate phthalate, which has a threshold pH of 5.0. In some embodiments, the pH sensitive polymer is hydroxypropyl methylcellulose phthalate, which has a threshold pH of 4.5-4.8. In some embodiments, the pH sensitive polymer is hydroxypropyl methylcellulose phthalate 50, which has a threshold pH of 5.2. In some embodiments, the pH-sensitive polymer is hydroxypropylmethylcellulose 55 phthalate, which has a threshold pH of 5.4. In some embodiments, the pH-sensitive polymer is cellulose acetate trimelliate, which has a threshold pH of 4.8. In some embodiments, the pH-sensitive polymer is cellulose acetate phthalate, which has a threshold pH of 5.0. In some embodiments, the delayed release composition comprises a combination of the above pH-sensitive polymers.
[0048] Those skilled in the art, having the benefit of this disclosure, will understand that other ingredients may be included to enhance one or more properties of the delayed release composition. In some embodiments, for example, the delayed release composition may include one or more disintegrants, lubricants, anti-caking additives, antibacterial agents, antifoaming agents, emulsifiers, surfactants, buffers, and / or colorants.
[0049] Suitable disintegrants include, for example, agar, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, povidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pregelatinized starch, clays, other algins, other celluloses, gums, and mixtures thereof. In some embodiments, the disintegrant is crospovidone. In some embodiments, the disintegrant is croscarmellose sodium.
[0050] Suitable lubricants include, for example, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, syloid silica gel (AEROSIL® 200, W. R. Grace Co., Baltimore, MD USA), coagulated aerosol of synthetic silica (Evonik Degussa Co., Plano, TX USA), pyrogenic silicon dioxide (CAB-O-SIL, Cabot Co., Boston, MA USA), and mixtures thereof.
[0051] Suitable anti-caking additives include, for example, calcium silicate, magnesium silicate, silicon dioxide, colloidal silicon dioxide, talc, glyceryl, and mixtures thereof.
[0052] For example, suitable antimicrobial additives that may be used as preservatives in the linaclotide compositions include, for example, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, butylparaben, cetylpyridinium chloride, cresol, chlorobutanol, dehydroacetic acid, ethylparaben, methylparaben, phenol, phenylethyl alcohol, phenoxyethanol, phenylmercuric acetate, phenylmercuric nitrate, potassium sorbate, propylparaben, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimersol, thymol, and mixtures thereof.
[0053] The composition may include any suitable pharma- ceutically acceptable carrier or vehicle. Suitable pharma-ceutically acceptable carriers include, for example, any solvent, dispersant, pH buffer, coating, absorption enhancer, controlled release agent, and one or more inert excipients (e.g., fillers, starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrants), and the like. In addition, the composition may contain any desired additional components, additives, and / or species, such as surface active additives, dispersion additives, humectants, suspending agents, solubilizers, buffers, disintegrants, preservatives, colorants, flavorings, and the like. In some embodiments, the composition includes one or more ionic species that interact with linaclotide.
[0054] The composition can include any suitable pH buffer. In some embodiments, the pH buffer is present in the composition in an amount sufficient to reach the isoelectric point of linaclotide. In this regard, the composition can have any desired pH. In some embodiments, the composition has a pH of 2 to 5 (e.g., a pH of 2 to 4.5, a pH of 2 to 4, a pH of 2.5 to 4, a pH of 2.5 to 3.5, a pH of 2.5 to 3, or even a pH of 3).
[0055] In some embodiments, the composition comprises linaclotide and a hydrolysis product, for example a hydrolysis product that includes or has the substructure: [ka]
[0056] The composition can contain any desired concentration of hydrolysis products. In some embodiments, the composition comprises less than 10 wt.% of hydrolysis products. In some embodiments, the composition comprises less than 7 wt.% of hydrolysis products. In some embodiments, the composition comprises less than 6 wt.% of hydrolysis products. In some embodiments, the composition comprises less than 5 wt.% of hydrolysis products. In some embodiments, the composition comprises less than 4 wt.% of hydrolysis products. In some embodiments, the composition comprises less than 3 wt.% of hydrolysis products. In some embodiments, the composition comprises less than 2 wt.% of hydrolysis products. In some embodiments, the composition comprises less than 1 wt.% of hydrolysis products. In some embodiments, the composition comprises 0.01-10 wt.% of hydrolysis products. In some embodiments, the composition comprises 0.1-7 wt.% of hydrolysis products. In some embodiments, the composition comprises 0.1-5 wt.% of hydrolysis products. In some embodiments, the composition comprises 0.5-5 wt.% of hydrolysis products. In some embodiments, the composition comprises 1-5 wt.% of hydrolysis products. In some embodiments, the composition comprises 0.1-4 wt.% of the hydrolysis product. In some embodiments, the composition comprises 0.5-4 wt.% of the hydrolysis product. In some embodiments, the composition comprises 1-4 wt.% of the hydrolysis product. In some embodiments, the composition comprises 0.1-3 wt.% of the hydrolysis product. In some embodiments, the composition comprises 0.5-3 wt.% of the hydrolysis product. In some embodiments, the composition comprises 1-3 wt.% of the hydrolysis product. In some embodiments, the composition comprises 0.1-2.5 wt.% of the hydrolysis product. In some embodiments, the composition comprises 0.5-2.5 wt.% of the hydrolysis product. In some embodiments, the composition comprises 1-2.5 wt.% of the hydrolysis product. In some embodiments, the composition comprises 0.1-2 wt.% of the hydrolysis product. In some embodiments, the composition comprises 0.5-2 wt.% of the hydrolysis product. In some embodiments, the composition comprises 1-2 wt.% of the hydrolysis product. In some embodiments, the composition comprises 0.1-1.5 wt.% of the hydrolysis product. In some embodiments, the composition comprises 0.5-1.5 wt.% of the hydrolysis product.In some embodiments, the composition comprises 0.1-1 wt.% of the hydrolysis product. In some embodiments, the composition comprises 0.5-1 wt.% of the hydrolysis product.
[0057] In some embodiments, the composition comprises linaclotide and an oxidation product, for example, an oxidation product that includes or has the following structure: [ka]
[0058] Alternatively or additionally, the composition comprises linaclotide and an oxidation product having the indicated structure above, but where oxidation occurs at any one or more of the six indicated cysteinyl sulfurs. The composition can contain any desired concentration of oxidation product. In some embodiments, the composition comprises less than 10 wt.% of the oxidation product. In some embodiments, the composition comprises less than 7 wt.% of the oxidation product. In some embodiments, the composition comprises less than 6 wt.% of the oxidation product. In some embodiments, the composition comprises less than 5 wt.% of the oxidation product. In some embodiments, the composition comprises less than 4 wt.% of the oxidation product. In some embodiments, the composition comprises less than 3 wt.% of the oxidation product. In some embodiments, the composition comprises less than 2 wt.% of the oxidation product. In some embodiments, the composition comprises less than 1 wt.% of the oxidation product. In some embodiments, the composition comprises 0.01-10 wt.% of the oxidation product. In some embodiments, the composition comprises 0.1-7 wt.% of the oxidation product. In some embodiments, the composition comprises 0.1-5 wt.% of the oxidation product. In some embodiments, the composition comprises 0.5-5 wt.% of the oxidation product. In some embodiments, the composition comprises 1-5 wt.% of the oxidation product. In some embodiments, the composition comprises 0.1-4 wt.% of the oxidation product. In some embodiments, the composition comprises 0.5-4 wt.% of the oxidation product. In some embodiments, the composition comprises 1-4 wt.% of the oxidation product. In some embodiments, the composition comprises 0.1-3 wt.% of the oxidation product. In some embodiments, the composition comprises 0.5-3 wt.% of the oxidation product. In some embodiments, the composition comprises 1-3 wt.% of the oxidation product. In some embodiments, the composition comprises 0.1-2.5 wt.% of the oxidation product. In some embodiments, the composition comprises 0.5-2.5 wt.% of the oxidation product. In some embodiments, the composition comprises 1-2.5 wt.% of the oxidation product. In some embodiments, the composition comprises 0.1-2 wt.% of the oxidation product. In some embodiments, the composition comprises 0.5-2 wt.% of the oxidation product. In some embodiments, the composition comprises 1-2 wt.% of the oxidation product. In some embodiments, the composition comprises 0.1-1.5 wt.% of the oxidation product.In some embodiments, the composition comprises 0.5-1.5 wt.% of the oxidation product. In some embodiments, the composition comprises 0.1-1 wt.% of the oxidation product. In some embodiments, the composition comprises 0.5-1 wt.% of the oxidation product.
[0059] In some embodiments, the composition comprises linaclotide and an acetylated product, for example, an acetylated product that includes or has the structure: [ka]
[0060] The composition can contain any desired concentration of the acetylation product. In some embodiments, the composition comprises less than 10 wt.% of the acetylation product. In some embodiments, the composition comprises less than 7 wt.% of the acetylation product. In some embodiments, the composition comprises less than 6 wt.% of the acetylation product. In some embodiments, the composition comprises less than 5 wt.% of the acetylation product. In some embodiments, the composition comprises less than 4 wt.% of the acetylation product. In some embodiments, the composition comprises less than 3 wt.% of the acetylation product. In some embodiments, the composition comprises less than 2 wt.% of the acetylation product. In some embodiments, the composition comprises less than 1 wt.% of the acetylation product. In some embodiments, the composition comprises 0.01-10 wt.% of the acetylation product. In some embodiments, the composition comprises 0.1-7 wt.% of the acetylation product. In some embodiments, the composition comprises 0.1-5 wt.% of the acetylation product. In some embodiments, the composition comprises 0.5-5 wt.% of the acetylation product. In some embodiments, the composition comprises 1-5 wt.% of the acetylation product. In some embodiments, the composition comprises 0.1-4 wt.% of the acetylated product. In some embodiments, the composition comprises 0.5-4 wt.% of the acetylated product. In some embodiments, the composition comprises 1-4 wt.% of the acetylated product. In some embodiments, the composition comprises 0.1-3 wt.% of the acetylated product. In some embodiments, the composition comprises 0.5-3 wt.% of the acetylated product. In some embodiments, the composition comprises 1-3 wt.% of the acetylated product. In some embodiments, the composition comprises 0.1-2.5 wt.% of the acetylated product. In some embodiments, the composition comprises 0.5-2.5 wt.% of the acetylated product. In some embodiments, the composition comprises 1-2.5 wt.% of the acetylated product. In some embodiments, the composition comprises 0.1-2 wt.% of the acetylated product. In some embodiments, the composition comprises 0.5-2 wt.% of the acetylated product. In some embodiments, the composition comprises 1-2 wt.% of the acetylated product. In some embodiments, the composition comprises 0.1-1.5 wt.% of the acetylation product.In some embodiments, the composition comprises 0.5-1.5 wt.% of the acetylated product. In some embodiments, the composition comprises 0.1-1 wt.% of the acetylated product. In some embodiments, the composition comprises 0.5-1 wt.% of the acetylated product.
[0061] In some embodiments, linaclotide and i. Peptide ("Cys 1 -IMD") or a pharma- ceutical acceptable salt thereof, [ka] a peptide comprising the amino acid structure ii. Hydrolyzed peptides ("Asp 7 ") or a pharma- ceutically acceptable salt thereof, [ka] a peptide comprising the amino acid structure iii. Acetylated peptides ("Cys 1 -N-acetyl) or a pharma- ceutical acceptable salt thereof, [ka] a peptide comprising the amino acid structure iv. A linaclotide trisulfide peptide or a pharma- ceutical acceptable salt thereof, comprising the amino acid sequence of Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr, wherein an additional sulfur atom may be attached to any one of the six cysteinyl sulfurs; v. Peptide ("Des-Tyr 14 ") or a pharma- ceutically acceptable salt thereof, [ka] or a peptide comprising the amino acid structure vi. Peptides (Cys 1 -α-ketone) or a pharma- ceutical acceptable salt thereof, [ka] A peptide comprising the amino acid structure and one or more peptides selected from the group consisting of
[0062] In some embodiments, Cys 1 The -α-ketone peptide may exist in its hydrated form or a pharma- ceutically acceptable salt thereof, and the peptide comprises the amino acid structure: [ka] Those skilled in the art will recognize that Cys 1 It will be appreciated that -α-ketone peptides readily convert between their hydrated and ketone forms.
[0063] In some embodiments, Cys 1 In another exemplary embodiment, the -α-ketone peptide comprises less than about 15% by weight of the composition, less than about 10% by weight of the composition, less than about 7% by weight of the composition, less than about 5% by weight of the composition, less than about 4% by weight of the composition, less than about 3% by weight of the composition, less than about 2% by weight of the composition, less than about 1.5% by weight of the composition, or less than about 1% by weight of the composition. 1 The -α-ketone peptide comprises from about 0.01% to about 15% by weight of the composition, from about 0.05% to about 10% by weight of the composition, from about 0.05% to about 7% by weight of the composition, or from about 0.05% to about 5% by weight of the composition.
[0064] In some embodiments, Cys 1 The -IMD peptide comprises less than about 15% by weight of the composition, less than about 10% by weight of the composition, less than about 7% by weight of the composition, less than about 5% by weight of the composition, less than about 4% by weight of the composition, less than about 3.5% by weight of the composition, less than about 3% by weight of the composition, less than about 2% by weight of the composition, or less than about 1% by weight of the composition. 1-IMD peptide comprises from about 0.01% to about 15% by weight of the composition, from about 0.05% to about 10% by weight of the composition, from about 0.05% to about 7% by weight of the composition, or from about 0.05% to about 5% by weight of the composition.
[0065] In some embodiments, the hydrolyzed peptide ("Asp 7 ") comprises less than about 15% by weight of the composition, less than about 10% by weight of the composition, less than about 7% by weight of the composition, less than about 5% by weight of the composition, less than about 4% by weight of the composition, less than about 3.5% by weight of the composition, less than about 3% by weight of the composition, less than about 2% by weight of the composition, or less than about 1% by weight of the composition. In other exemplary embodiments, hydrolyzed peptides ("Asp 7 ") constitutes from about 0.01% to about 15% by weight of the composition, from about 0.05% to about 10% by weight of the composition, from about 0.05% to about 7% by weight of the composition, or from about 0.05% to about 5% by weight of the composition.
[0066] In some embodiments, an acetylated peptide ("Cys 1 -N-acetyl") comprises less than about 15% by weight of the composition, less than about 10% by weight of the composition, less than about 7% by weight of the composition, less than about 5% by weight of the composition, less than about 4% by weight of the composition, less than about 3.5% by weight of the composition, less than about 3% by weight of the composition, less than about 2% by weight of the composition, or less than about 1% by weight of the composition. In other exemplary embodiments, the acetylated peptide ("Cys 1 -N-acetyl) comprises from about 0.01% to about 15% by weight of the composition, from about 0.05% to about 10% by weight of the composition, from about 0.05% to about 7% by weight of the composition, or from about 0.05% to about 5% by weight of the composition.
[0067] In some embodiments, the linaclotide trisulfide peptide comprises less than about 15% by weight of the composition, less than about 10% by weight of the composition, less than about 7% by weight of the composition, less than about 5% by weight of the composition, less than about 4% by weight of the composition, less than about 3.5% by weight of the composition, less than about 3% by weight of the composition, less than about 2% by weight of the composition, or less than about 1% by weight of the composition. In other exemplary embodiments, the linaclotide trisulfide peptide comprises from about 0.01% to about 15% by weight of the composition, from about 0.05% to about 10% by weight of the composition, from about 0.05% to about 7% by weight of the composition, or from about 0.05% to about 5% by weight of the composition.
[0068] In some embodiments, Des-Tyr 14 The peptide comprises less than about 15% by weight of the composition, less than about 10% by weight of the composition, less than about 7% by weight of the composition, less than about 5% by weight of the composition, less than about 4% by weight of the composition, less than about 3.5% by weight of the composition, less than about 3% by weight of the composition, less than about 2% by weight of the composition, or less than about 1% by weight of the composition. 14 The peptide comprises about 0.01% to about 15% by weight of the composition, about 0.05% to about 10% by weight of the composition, about 0.05% to about 7% by weight of the composition, or about 0.05% to about 5% by weight of the composition.
[0069] In some embodiments, the composition comprises linaclotide and any desired concentration of multimers. In some embodiments, the composition comprises less than 10 wt.% multimer(s). In some embodiments, the composition comprises 0.5-1 wt.% multimer(s).
[0070] In some embodiments, the composition comprises an effective amount of linaclotide and any desired amount of reduced linaclotide. As used herein, the term "reduced linaclotide" refers to linaclotide that does not have disulfides between cysteine amino acids. In some embodiments, the composition comprises less than 10 wt.% reduced linaclotide. In some embodiments, the composition comprises 0.5-1 wt.% reduced linaclotide.
[0071] In some embodiments, the composition comprises an effective amount of linaclotide and any desired amount of scrambled linaclotide. As used herein, the term "scrambled linaclotide" refers to a compound that is a linaclotide derivative ... 10 Between Cys1 and Cys 13 between Cys1 and Cys5, between Cys1 and Cys2, between Cys2 and Cys6, between Cys2 and Cys 13 between Cys2 and Cys5, between Cys5 and Cys6, and / or between Cys5 and Cys 10 This refers to linaclotide having a disulfide bond between the linaclotide and the scrambled linaclotide. In some embodiments, the composition comprises 0.5 to 1 wt.% scrambled linaclotide. In some embodiments, the composition comprises less than 10 wt.% scrambled linaclotide.
[0072] In some embodiments, the composition has a total degradant concentration of less than about 10 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 8 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 7 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 6.5 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 6 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 5.5 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 5 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 4 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 3 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 2.5 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 2 wt.%. In some embodiments, the composition has a total degradant concentration of less than about 1 wt.%.
[0073] In some embodiments, the compositions can be prepared by spray drying, a technique used to prepare microparticles (e.g., microcapsules or microspheres) of drugs. Spray-dried peptides generally retain their biological activity upon dissolution and can have useful physical properties, including uniform particle size and spherical shape. In addition, microparticles prepared by spray drying are often free-flowing, which is useful for pharmaceutical manufacturing processes such as tablet formation and capsule filling. Spray drying processes are also useful because they are easily scalable for clinical and commercial manufacturing. In one embodiment, the spray buffer includes HCl, histidine, 1.5% PVA, and 0.6% talc. This formulation can be used to provide a lower dosage range of 36-290 μg.
[0074] When administered, the composition will dissolve and release linaclotide in the target area of the gastrointestinal tract. The formulation may release linaclotide over a period of time that depends on several different factors. These factors include the dimensions of the formulation, the concentration of linaclotide, and how linaclotide is distributed throughout the formulation. For example, the dissolution rate can be adjusted by varying the thickness and surface area of the formulation. A thicker formulation will dissolve slower than an otherwise similar thinner formulation and may be desirable for administering high doses of linaclotide.
[0075] In some embodiments, the delayed release composition has a disintegration rate of less than about 60 minutes at the target pH condition. In some embodiments, the delayed release composition has a disintegration rate of less than about 30 minutes at the target pH condition. In some embodiments, the delayed release composition has a disintegration rate of less than about 25 minutes at the target pH condition. In some embodiments, the delayed release composition has a disintegration rate of less than about 20 minutes at the target pH condition. In some embodiments, the delayed release composition has a disintegration rate of less than about 15 minutes at the target pH condition. In some embodiments, the delayed release composition has a disintegration rate of less than about 10 minutes at the target pH condition. In some embodiments, the delayed release composition disintegrates in less than about 30 minutes after entering the target environment. In some embodiments, the delayed release composition disintegrates in less than about 25 minutes after entering the target environment. In some embodiments, the delayed release composition disintegrates in less than about 20 minutes after entering the target environment. In some embodiments, the delayed release composition disintegrates in less than about 15 minutes after entering the target environment.
[0076] In some embodiments, the delayed release composition releases at least about 75% of the linaclotide contained therein within 60 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 75% of the linaclotide contained therein within 30 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 80% of the linaclotide contained therein within 30 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 85% of the linaclotide contained therein within 30 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 90% of the linaclotide contained therein within 30 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 95% of the linaclotide contained therein within 30 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 99% of the linaclotide contained therein within 30 minutes of entering the target environment.
[0077] In some embodiments, the delayed release composition releases at least about 40% of the linaclotide contained therein within 15 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 50% of the linaclotide contained therein within 15 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 60% of the linaclotide contained therein within 15 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 70% of the linaclotide contained therein within 15 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 80% of the linaclotide contained therein within 15 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 85% of the linaclotide contained therein within 15 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 90% of the linaclotide contained therein within 15 minutes of entering the target environment. In some embodiments, the delayed release composition releases at least about 95% of the linaclotide contained therein within 15 minutes of entering the target environment.
[0078] In some embodiments, the delayed release composition releases at least about 80% of the linaclotide contained therein in about 2 to about 2 hours after entry into the target environment.
[0079] In some embodiments, the delayed release composition releases at least about 75% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 5. In some embodiments, the delayed release composition releases at least about 80% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 5. In some embodiments, the delayed release composition releases at least about 85% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 5. In some embodiments, the delayed release composition releases at least about 90% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 5. In some embodiments, the delayed release composition releases at least about 95% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 5. In some embodiments, the delayed release composition releases at least about 99% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 5.
[0080] In some embodiments, the delayed release composition releases at least about 75% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 7. In some embodiments, the delayed release composition releases at least about 80% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 7. In some embodiments, the delayed release composition releases at least about 85% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 7. In some embodiments, the delayed release composition releases at least about 90% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 7. In some embodiments, the delayed release composition releases at least about 95% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 7. In some embodiments, the delayed release composition releases at least about 99% of the linaclotide contained therein within 30 minutes of contact with a pH greater than 7.
[0081] In some embodiments, the linaclotide DR compositions are formulated for delivery of linaclotide to the ileum, terminal ileum, or colon.
[0082] In some embodiments, the linaclotide DR compositions are formulated for delivery of linaclotide to the colon.
[0083] The composition can be used to treat other diseases, disorders, or conditions that are responsive to treatment with GC-C receptor agonists.The composition can be used to treat any gastrointestinal disorder and / or condition or inflammation or pain associated therewith in a patient (e.g., a mammal or human).The delayed release composition of the present invention can be used to treat a variety of conditions, but is particularly suitable for treating gastrointestinal disorders, such as irritable bowel syndrome ("IBS") (e.g., IBS with constipation "IBS-c", IBS with diarrhea "IBS-d", or mixed IBS with constipation and diarrhea "IBS-m"), constipation (e.g., chronic idiopathic constipation), colon cancer, diverticulitis, interstitial cystitis, and abdominal or visceral pain.
[0084] Such suitable gastrointestinal disorders and conditions include, but are not limited to, irritable bowel syndrome, irritable bowel syndrome with constipation, colon cancer, dyspepsia (including functional dyspepsia or non-ulcer dyspepsia), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, gastroparesis, chronic intestinal pseudo-obstruction (or pseudo-colonic obstruction), as well as disorders and conditions related to constipation, such as chronic constipation, opioid-induced constipation, post-operative constipation (post-operative ileus), and constipation associated with a neuropathic disorder or combinations of symptoms thereof (such as a combination of irritable bowel syndrome and chronic constipation), constipation associated with a neuropathic disorder (e.g., constipation associated with Parkinson's disease), constipation associated with cystic fibrosis or thyroid disease. In some embodiments, a method is provided for treating a gastrointestinal disorder in a patient (e.g., a mammal or a human) diagnosed with one or more gastrointestinal disorders or conditions, comprising administering to the patient an effective amount of the composition.
[0085] In some embodiments, a method for treating a gastrointestinal disorder comprises administering to a patient in need of treatment a therapeutically effective amount of a composition described herein. The gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome (IBS), constipation, functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, inflammatory bowel disease, dyspepsia, diverticulitis pain, visceral or abdominal pain, prostatitis, testicular pain, abdominal or visceral inflammation, painful bladder syndrome, endometriosis, vulvodynia, or rectal pain. In some embodiments, the constipation is chronic constipation, idiopathic constipation, chronic idiopathic constipation, constipation due to postoperative ileus, or constipation due to opiate use. In other embodiments, the irritable bowel syndrome is irritable bowel syndrome with constipation (IBS-c), irritable bowel syndrome with diarrhea (IBS-d), or mixed irritable bowel syndrome (IBS-m).
[0086] In some embodiments, the compositions can be used to treat constipation, irritable bowel syndrome associated with constipation, and visceral pain, hi other embodiments, the compositions can be used to preferentially treat visceral or abdominal pain over other GI disorder symptoms.
[0087] As mentioned above, linaclotide has been previously shown to reduce abdominal pain, which is believed to be mediated by cGMP to the submucosal / basolateral space. However, due to the reducing environment of the intestinal tract, much of the oral linaclotide dose is believed to be degraded before reaching the distal colon. In human volunteers treated with linaclotide, only about 5% of the oral dose is found in the stool. The compositions described herein are delayed release ("DR") compositions of linaclotide that target the lower GI, allowing for higher doses of linaclotide to be delivered to the colon, thereby improving the efficacy of linaclotide in relieving various GI disorder-related pain. As such, in one embodiment, the compositions described herein are useful for treating the lower GI.
[0088] The DR composition of linaclotide will have the potential to release linaclotide mainly (completely) in the lower GI. As a result, for example, the DR formulation or composition will have a high ability to treat lower GI-related disorders. Furthermore, for example, by not activating GC-C receptors in the upper GI, it will result in less overall intestinal fluid secretion, and therefore may have the ability to produce a lower incidence of adverse events (e.g., diarrhea) than immediate release dosage forms. This will at the same time maintain or even improve the effectiveness of linaclotide to treat symptoms of GI disorders, such as pain.
[0089] In some embodiments, the compositions described herein are useful for treating diseases or conditions associated with visceral pain selected from the group consisting of general abdominal pain, diverticular disease, irritable bowel syndrome (IBS)-related pain, chronic or acute radiation rectal injury (also called radiation proctitis), rectal pain, chronic perianal pain, resolving anorectal pain, anal pain, chronic anal fissure, postoperative anal pain, overactive bladder syndrome, stress urinary incontinence, interstitial cystitis, bladder pain syndrome, cancer-related pain, gastrointestinal neoplasm-related pain, general pelvic pain, endometriosis, testicular pain, chronic prostatitis, prostatic pain, vulvar pain, urethral syndrome, penile pain, perianal pain, ulcerative colitis, ulcerative proctitis, and Crohn's disease. In one particular embodiment, the compositions described herein are useful for treating bladder pain syndrome. In another particular embodiment, the compositions described herein are useful for treating overactive bladder syndrome, including, for example, bladder hypersensitivity or colitis-induced bladder afferent hyperactivity.
[0090] In yet another embodiment, the compositions described herein are useful for treating interstitial cystitis. In yet another embodiment, the compositions described herein are useful for treating endometriosis. In another embodiment, the compositions described herein are useful for treating anal pain.
[0091] In some embodiments, a method of treating a disorder is provided, comprising administering to a patient in need of treatment a therapeutically effective amount of a composition described herein. In some embodiments, the disorder is a cancer selected from colorectal / regionally metastatic colorectal cancer, intestinal polyps, Barrett's esophagus, gastrointestinal tract cancer, lung cancer, cancer of epithelial cells or precancerous or metastatic growths, polyps, breast cancer, colorectal cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, stomach cancer, bladder cancer, liver cancer, esophageal cancer, and testicular cancer.
[0092] In some embodiments, a method for preventing cancer or hyperplasia of the gastrointestinal tract or preventing the recurrence of cancer or hyperplasia of the gastrointestinal tract in a patient in need of such prevention is provided, comprising administering to the patient an effective amount of the composition or oral dosage form. In some embodiments, the cancer or hyperplasia is colorectal cancer, intestinal polyps, or precancerous or metastatic growth of gastrointestinal epithelial cells. In some embodiments, the composition or oral dosage form is administered simultaneously or sequentially with an effective amount of a COX-2 inhibitor. Examples of highly selective and selective COX-2 inhibitors include etoricoxib, rofecoxib, lumiracoxib, valdecoxib, celecoxib (Celebrex®), sulindac, diclofenac, meloxicam, and etodolac. Nonselective NSAIDs that inhibit COX-2 include naproxen, ibuprofen, sodium salicylate, and diflunisal. As used herein, the terms "prevent" or "preventing" mean arresting, delaying the onset (i.e., the period before clinical symptoms of disease) or recurrence of cancer or hyperplasia, and / or reducing the risk of developing cancer or hyperplasia, as compared to a patient who has not been treated with a composition described herein.
[0093] In some embodiments, the compositions and oral dosage forms described herein provide a method of treating gastrointestinal disorders in a pediatric patient. In some embodiments, the compositions and oral dosage forms described herein provide a method of treating gastrointestinal disorders in a pediatric patient diagnosed with one or more gastrointestinal disorders or conditions, comprising administering to the patient an effective amount of the compositions or oral dosage forms. In some embodiments, the compositions and oral dosage forms described herein are used to treat conditions including, but not limited to, GI motility disorders, irritable bowel syndrome, constipation-predominant irritable bowel syndrome (IBS-c), mixed irritable bowel syndrome (IBS-m), chronic constipation, chronic idiopathic constipation, opioid-induced constipation, post-operative constipation (post-operative ileus), constipation associated with neuropathic disorders, constipation associated with cystic fibrosis or thyroid disease, dyspepsia (including functional dyspepsia or non-ulcer dyspepsia), gastroparesis, gastrointestinal disorders, inflammatory bowel disorders, and the like. Methods of using the compositions and oral dosage forms to treat gastrointestinal disorders including motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), inflammatory bowel disease, Crohn's disease, ulcerative colitis, functional heartburn, chronic intestinal pseudo-obstruction (or pseudo-colonic obstruction), visceral pain, abdominal pain, pelvic pain, anal fissure pain, vulvodynia-related pain, endometriosis-related pain, fibromyalgia-related pain, functional abdominal pain, interstitial cystitis pain, diverticulitis, diverticulitis-related pain, and celiac sprue-related pain are provided. In some embodiments, methods of treating IBS-c, IBS-m, or chronic constipation (e.g., chronic idiopathic constipation) in a pediatric patient with the compositions and oral dosage forms described herein are provided. In some embodiments, methods of treating a pediatric patient in need of treatment for IBS-c are provided. In some embodiments, methods of treating a pediatric patient in need of treatment for chronic idiopathic constipation are provided.
[0094] In some embodiments, the method is a method for treating or alleviating pain in a patient in need thereof, comprising administering a therapeutically effective amount of a composition as described herein. In some embodiments, the pain is selected from visceral pain; abdominal pain; pelvic pain; or pain associated with gastrointestinal disorders, sexually transmitted diseases, bladder pain syndrome, diverticulitis pain, prostatitis, testicular pain, endometriosis, vulvodynia, rectal pain, or interstitial cystitis. In some embodiments, the pain is selected from pelvic pain, proctitis-related pain, anal fissure pain, vulvodynia-related pain, endometriosis-related pain, fibromyalgia-related pain, functional abdominal pain, interstitial cystitis pain, sexually transmitted diseases-related pain, diverticulitis, diverticulitis-related pain, and celiac sprue-related pain.
[0095] In another embodiment, the method is for increasing intestinal motility in a patient in need thereof, comprising administering to the patient an effective amount of the composition. Intestinal motility involves the spontaneous uncoordinated contractions of the stomach, intestines, colon and rectum to move food through the gastrointestinal tract during the digestive process. In some embodiments, the disorder is post-operative ileus, or constipation due to opiate use.
[0096] In an exemplary embodiment, the method may include administering a therapeutically effective amount of a pharmaceutical composition to a patient in need thereof. The effective amount of a composition comprising linaclotide or a pharma- ceutically acceptable salt thereof required to achieve a desired outcome in a subject (such as a desired treatment and / or symptom relief) will depend on several understood factors, such as the identity and severity of the disorder being treated, as well as the age, weight, and other factors of the patient being treated.
[0097] In some embodiments, the composition or oral dosage form is administered to a pediatric patient in need thereof as a tablet, capsule or sachet. In some embodiments, a sachet containing the composition is opened and the contents are sprinkled or stirred into food, such as applesauce, or into food, such as applesauce, or into a drink, such as water. In some embodiments, a capsule is swallowed whole with a fluid, such as water, or the capsule is opened and sprinkled or stirred into food or drink. Tablets can be swallowed whole, crushed and stirred into food or drink, or can be formulated as chewable tablets.
[0098] The subject or patient to whom the administration of the pharmaceutical composition is an effective treatment regimen for a disease or disorder is preferably a human, but may be any animal, including laboratory animals in the context of clinical trials or screening or activity experiments.Thus, as one skilled in the art can easily understand, the methods, compounds and compositions described herein are particularly suitable for administration to any animal, particularly mammals, including, but not limited to, humans, rodents and non-rodents, such as feline or canine subjects, domestic animals, such as but not limited to, bovine, equine, caprine, ovine and porcine subjects, wild animals (whether in the wild or in zoos), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, and bird species, such as chickens, turkeys, and poultry for veterinary medical use.
[0099] In some embodiments, the linaclotide composition can be formulated as a rectal dosage form for rectal administration. Rectal dosage forms include, but are not limited to, rectal suppositories, rectal foams or aerosols, enemas, rectal gels, and rectal ointments. In some embodiments, the rectal dosage form can be administered to a patient in need of administration. In some embodiments, the rectal dosage form can be administered to a patient to treat abdominal or rectal pain, pain from anal fissures, ulcerative colitis, Crohn's disease, or inflammatory bowel disease. In some embodiments, the rectal dosage form can be administered to a pediatric patient or an elderly patient.
[0100] In some embodiments, the effective dose range for linaclotide for adult humans is 25 μg to 6 mg per day orally. In some embodiments, the dose range is 15 μg to 2 mg per day orally. In some embodiments, the dose range for adult humans is 50 μg to 1 mg per day orally (e.g., 15 μg, 30 μg, 50 μg, 72 μg, 100 μg, 145 μg, 150 μg, 200 μg, 250 μg, 290 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 550 μg, 579 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900 μg, 950 μg or 1 mg). In some embodiments, the dose range for an adult human is 30 μg to 300 μg orally per day. In some embodiments, the dose range is 100 μg to 600 μg orally per day. In some embodiments, the dose is 30 μg, 100 μg, 150 μg, 200 μg, 300 μg, 400 μg, 500 μg, or 600 μg of linaclotide orally per day. In some embodiments, the dose is 50 μg of linaclotide orally per day. In some embodiments, the dose is 100 μg of linaclotide orally per day. In some embodiments, the dose is 145 μg of linaclotide orally per day. In some embodiments, the dose is 200 μg of linaclotide orally per day. In some embodiments, the dose is 290 μg of linaclotide orally per day. In some embodiments, the dose is 300 μg of linaclotide per day, orally. In some embodiments, the dose is 500 μg of linaclotide per day, orally. In some embodiments, the dose is 600 μg of linaclotide per day, orally.
[0101] In some embodiments, the effective pediatric dose range of linaclotide is 0.05 μg to 2 mg per day, orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.05 μg to 100 μg per day, orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.1 μg to 90 μg per day, orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.1 μg to 50 μg per day, orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.1 μg to 25 μg per day, orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.1 μg to 10 μg per day, orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.1 μg to 5 μg per day, orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.1 μg to 1 μg orally per day. In some embodiments, the effective pediatric dose range of linaclotide is 0.1 μg to 0.5 μg orally per day. In some embodiments, the effective pediatric dose range of linaclotide is 0.1 μg orally per day. In some embodiments, the effective pediatric dose range of linaclotide is 0.15 μg orally per day. In some embodiments, the effective pediatric dose range of linaclotide is 0.25 μg orally per day. In some embodiments, the effective pediatric dose range of linaclotide is 0.5 μg orally per day. In some embodiments, the effective pediatric dose range of linaclotide is 3.5 μg orally per day. In some embodiments, the effective pediatric dose range of linaclotide is 15 μg orally per day. In some embodiments, the effective pediatric dose range of linaclotide is 36 μg orally per day. In some embodiments, the effective pediatric dose range of linaclotide is 45 μg per day, orally. In some embodiments, the effective pediatric dose range of linaclotide is 60 μg per day, orally. In some embodiments, the effective pediatric dose range of linaclotide is 90 μg per day, orally. In some embodiments, the unit dosage form and the daily dose are equivalent.
[0102] In some embodiments, the unit dosage form is administered with food at any time of the day, without food at any time of the day, or with food after overnight fasting (e.g., with breakfast). In some embodiments, the unit dosage form is administered once a day, twice a day, or three times a day. In some embodiments, one, two, or three unit dosage forms will contain a daily oral dose of linaclotide. The exact amount of compound administered to a patient is the responsibility of the attending physician. However, the dosage used will depend on several factors, including the age and sex of the patient, the exact disorder being treated, and its severity.
[0103] In some embodiments, the composition is administered as a monotherapy. In some embodiments, the composition consists essentially of an effective amount of linaclotide. In some embodiments, the composition consists of an effective amount of linaclotide.
[0104] In some embodiments, the composition is administered directly to the patient, for example, in the form of a delayed release tablet or delayed release capsule. In some embodiments, the composition is dissolved, disintegrated and / or mixed on or in food or drink before administration to the patient (e.g., elderly or pediatric patient). In some embodiments, the composition is dissolved or disintegrated in a liquid, solution or fluid containing stabilizer(s), preservative(s), sweetener(s) and the like as needed before administration to the patient (e.g., elderly or pediatric patient). In some embodiments, the composition is a multi-dose composition, i.e., containing 2, 3, 5, 7, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90 or more daily doses of linaclotide.
[0105] In other embodiments, the compositions are administered as part of a combination therapy. For example, the compositions may be used in combination with other drugs or therapies used to treat, prevent, inhibit, and / or ameliorate a disease or condition for which the compounds of the present invention are useful. Linaclotide can be co-administered or coformulated with other medications. In one embodiment, the linaclotide composition can be co-administered with other medications used to treat gastrointestinal disorders, including, but not limited to, acid suppressants such as histamine-2 receptor agonists (H2A) and / or proton pump inhibitors (PPIs). In one embodiment, the linaclotide composition can be co-administered with other medications used to treat gastrointestinal disorders, including 5-ASAs such as mesalamine.
[0106] Therefore, such other drug(s) can be used simultaneously or sequentially with the compound of the present invention by a route and amount commonly used.When the compound of the present invention is used simultaneously with one or more other drugs, a pharmaceutical unit dosage form containing the other drugs in addition to the compound of the present invention can be used.Therefore, the pharmaceutical composition of the present invention includes a pharmaceutical composition that contains one or more other active ingredients in addition to the compound of the present invention.
[0107] Several methods can be used to assess the biological activity of linaclotide compositions, including, but not limited to, immunoassays (e.g., enzyme-linked immunosorbent assays), radioimmunoassays, immunoradiometric assays, gel electrophoresis (e.g., SDS-PAGE), high performance liquid chromatography (HPLC), and / or high performance capillary electrophoresis (HPCE). In some embodiments, the biological activity of the composition is assessed by a method that includes immobilizing linaclotide, incubating linaclotide with guanylate cyclase C (GCC), incubating GCC-bound linaclotide with an antibody against GCC, incubating GCC antibody-bound linaclotide with a fluorescently labeled antibody against GCC antibody, and detecting linaclotide bound to the GCC antibody by measuring the fluorescence intensity using a plate reader. The drug concentration can then be calculated based on the fluorescence readings of the solution.
[0108] For example, the biological activity of linaclotide compositions can be evaluated and quantified using the following method, although other methods are also available. The composition is added to a volumetric flask containing 60 ml of phosphate buffer with a pH of 4.5, and the flask is shaken for 60 minutes. 0.2 ml of the supernatant is then removed and added to one or more wells of a 96-well plate coated with GC-C receptor. The plate is sealed and incubated at 37° C. for 2 hours. At the end of the incubation, the sample is removed and the plate is washed with phosphate-buffered saline (PBS). The bound linaclotide is then incubated with fluorescein isocyanate (FITC)-labeled GC-C (e.g., available from Sigma-Aldrich Inc.) in blocking buffer for 1 hour at room temperature. After incubation, the wells are washed with PBS. The fluorescence intensity of the final product is detected, for example, using a plate reader. The linaclotide concentration is then calculated based on the fluorescence reading of the solution.
[0109] definition As used herein, unless otherwise specified, the term "delayed release" means that the composition dissolves, melts, disintegrates, liquefies, etc. in the targeted region of the gastrointestinal tract such that substantially all of the linaclotide no longer remains in the formulation, composition, or dosage form. Delayed release compositions include sustained release compositions, gastroretentive compositions, targeted release compositions (such as, for example, colonic release compositions, or compositions that target the ileocecal valve), extended release compositions, and / or combinations thereof.
[0110] As used herein, unless otherwise specified, the term "delayed release composition" ("DR") means that the composition is a dosage form that releases linaclotide at a time other than immediately after oral administration.
[0111] As used herein, unless otherwise specified, the term "extended release composition" means that the composition is in a dosage form that releases linaclotide over an extended period of time after administration, which allows for less frequent administration compared to immediate release compositions.
[0112] As used herein, unless otherwise specified, "disintegration" and "release" are used herein to mean that a capsule, film, bead, or tablet containing linaclotide dissolves, melts, disintegrates, liquefies, etc., such that substantially all of the linaclotide no longer remains in the formulation, e.g., at a pH greater than 5 or 7, or in a phosphate buffer solution and in the oral environment maintained at 37±1°C.
[0113] When referring to the release of linaclotide from a composition, unless otherwise specified, the term "released from" is used herein to mean that the linaclotide no longer remains in the form of the composition.
[0114] As used herein, unless otherwise specified, the term "entering the target environment" refers to contact of the composition within the patient in the target organ or segment thereof, or within a segment of the GI having a pH greater than 5 or 7, for example, where linaclotide release is intended.
[0115] As used herein, unless otherwise specified, the term "lower gastrointestinal (GI)" means the distal segment of the gastrointestinal tract, e.g., the ileum, terminal ileum, ileocecal valve, or colon.
[0116] As used herein, unless otherwise specified, the term "upper gastrointestinal (GI)" means the proximal segments of the gastrointestinal tract, eg, the stomach, duodenum, and / or jejunum.
[0117] As used herein, unless otherwise specified, "stabilizer" refers to a polymer, a sterically hindered primary amine (e.g., amino acid), or a cationic (e.g., metal cation) component of the composition that is included in the composition in a stabilizing amount. For example, a polymeric stabilizer is a polymer that is included in the composition in a stabilizing amount. Similarly, a sterically hindered primary amine stabilizer is a sterically hindered primary amine that is included in the composition in a stabilizing amount. Additionally, a cationic stabilizer is a cation that is included in the composition in a stabilizing amount.
[0118] As used herein, unless otherwise specified, a "stabilizing amount" refers to the concentration of a polymer, sterically hindered primary amine (e.g., amino acid), or metal cation component within a composition at which the component increases the stability of linaclotide in the composition compared to a similar composition that does not have a stabilizing amount of the same component.
[0119] As used herein, unless otherwise specified, the term "substantially all" means at least about 90%, such as at least about 95% or even at least about 99%.
[0120] As used herein, unless otherwise specified, the terms "isolated and purified" mean at least 95 percent pure (e.g., at least 96% pure, at least 97% pure, at least 98% pure, or even at least 99% pure) as measured by chromatographic purity, e.g., using HPLC.
[0121] As used herein, unless otherwise specified, a "therapeutically effective amount" refers to an amount of linaclotide or a pharma- ceutically acceptable salt thereof that, when administered to a mammal for treating a condition, disorder, or pathology, is sufficient to effect treatment (as defined below). A "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, sex, weight, health, and responsiveness of the mammal to be treated. For example, a therapeutically effective amount of linaclotide, or a pharma- ceutically acceptable salt or hydrate thereof, can be an amount effective to treat gastrointestinal disorders, including irritable bowel syndrome, constipation-predominant irritable bowel syndrome, chronic constipation, opioid-induced constipation, and / or dyspepsia.
[0122] As used herein, unless otherwise specified, "pharmaceutical acceptable" means biologically or pharmaceutical compatible for in vivo use in animals or humans, and preferably means approved by a federal or state government regulatory agency or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, and more particularly humans.
[0123] As used herein, unless otherwise specified, the term "treat" in all its verb forms means to alleviate, reduce, prevent, and / or manage at least one symptom of a subject disorder, including, for example, gastrointestinal disorders such as irritable bowel syndrome, constipation-predominant irritable bowel syndrome, chronic constipation, opioid-induced constipation, dyspepsia, or a combination of symptoms thereof. Within the meaning of the present invention, the term "treat" also means to arrest, delay the onset (i.e., the period before the clinical symptoms of disease) and / or reduce the risk of developing or worsening a disease. The term "treatment" refers to the act of "treating" as defined above.
[0124] As used herein, unless otherwise specified, the term "additive" refers to a pharma- ceutically acceptable additive. Pharmaceutically acceptable additives include, but are not limited to, binders, disintegrants, dispersing additives, lubricants, glidants, antioxidants, coating additives, diluents, surfactants, flavor additives, humectants, absorption enhancers, controlled release additives, anti-caking additives, antimicrobial agents (e.g., preservatives), colorants, desiccants, plasticizers, and dyes.
[0125] As used herein, unless otherwise specified, an "excipient" is any pharma- ceutically acceptable additive, filler, binder, or agent.
[0126] As used herein, unless otherwise specified, "stress conditions" refers to 40° C. and 75% relative humidity (RH).
[0127] As used herein, unless otherwise specified, the terms "about" and "approximately" mean within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within one or more standard deviations through the practice of the art. Alternatively, with respect to a composition, "about" can mean up to plus or minus 20% of a range, preferably up to 10%. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Particular values are described in the present specification and claims, and unless otherwise specified, the term "about" means within an acceptable error range for the particular value.
[0128] All weight percentages referred to herein (i.e., "weight %" and "wt.%" and w / w) are measured relative to the total weight of the pharmaceutical composition, unless otherwise specified.
[0129] As used herein, when used to refer to a composition, the term "consisting essentially of" and variations thereof is used to mean that the composition comprises linaclotide and other desired pharma- ceutically inactive additives, excipients, and / or ingredients (e.g., polymers, sterically hindered primary amines, cations, fillers, binders, carriers, excipients, diluents, disintegration additives, lubricants, solvents, dispersants, coating additives, absorption enhancing additives, hydrolysis products, formaldehyde imine products, oxidation products, acetylation products, ami- dation products, multimers, controlled release additives, anti-caking additives, antimicrobial additives, preservatives, sweetening additives, colorants, flavorings, desiccants, plasticizers, dyes, etc.), and is free of other active pharmaceutical ingredient(s). EXAMPLES
[0130] Working Example Since numerous variations and equivalents encompassed by this invention will become apparent to those of skill in the art upon reading this disclosure, the following examples are merely illustrative of the invention and should not be construed as limiting the scope of the invention in any way.
[0131] Enteric coated tablets, including core immediate release tablets containing a unit dose of linaclotide, can be coated with a coating that dissolves only under the pH conditions of the distal segment of the intestine, resulting in release of linaclotide in the lower GI tract.
[0132] Linaclotide, or a pharma- ceutically acceptable salt thereof, can be prepared and purified using standard techniques known in the art, for example, chemical synthesis or recombinant expression followed by purification using standard techniques.
[0133] Preparation of linaclotide coating solution for beads: Approximately 32g-42g of purified water is mixed with hydrochloric acid to produce a solution with a pH of 1.5-2.0. If a cation is used, the cation is added to the solution in an amount to give the desired concentration and the solution is mixed for a sufficient time to provide a clear solution. If a sterically hindered primary amine is used, the sterically hindered primary amine is added to the solution in an amount to give the desired concentration and the solution is mixed for a sufficient time to provide a clear solution. Other additives such as antioxidants are then added, if necessary. The pH of the solution is checked and, if necessary, hydrochloric acid is added to produce a solution having a pH of 1.5-2.0. A binder is then added to the solution and the mixture is stirred for a sufficient time to provide a clear solution. The desired amount of linaclotide is added to the solution and mixed for 30-100 minutes to provide the coating solution.
[0134] In one embodiment, the coating solution includes linaclotide, histidine, 1.5% PVA and 0.6% talc. A dosage range of 30-300 μg can be produced using this formulation.
[0135] Preparation of active beads: Approximately 30-36 g of dry microcrystalline cellulose beads are added to a mini-column fluid bed coater. The microcrystalline cellulose beads are fluidized and heated before layering. The coating solution is then layered onto the beads. The spray temperature is controlled between 24°C and 55°C by controlling the inlet temperature, spray rate, atomization pressure, and air volume. After the entire coating solution is layered onto the beads, the beads are dried. The product of this process is called active beads.
[0136] Example 1 Delayed-release linaclotide tablets Linaclotide can be formulated into tablets for delayed drug release. Compared to beads of equivalent volume, tablets have a much smaller specific surface area, which may reduce the tendency of tablets to decompose induced by environmental factors such as moisture, oxidation, deamidation, etc. Furthermore, the smaller surface area of tablets can be advantageous when enteric coating is required, as much less coating material is needed to cover the surface of the dosage form.
[0137] An enteric coating may be added to a tablet coating pan and the coating used for the delayed release beads may be used for the tablets to form delayed release tablets. The amount of coating polymer on the tablet may vary from 5 to 60% (weight gain) depending on the size, shape and surface properties of the tablet. A subcoat may be applied to the tablet to separate the linaclotide from the enteric or functional coat.
[0138] Example 2 Enteric coated tablets [Table 1]
[0139] Manufacturing Process: A. Tablets The granulation solution can be prepared by dissolving PVP, histidine and calcium chloride in water, adjusting the pH to 2, and dissolving linaclotide. Granulation is carried out by spraying the granulation solution onto the filler isomalt in a fluidized bed. At the end of granulation, the granules are dried for 30 minutes. The granules are then blended with tablet ingredients including isomalt, crospovidone, magnesium stearate and talc until uniform and compressed into tablets.
[0140] B. Enteric Coating For tablet coating, the linaclotide core tablets are placed in a pan coater and warmed to 35° C. Tablet coating with Eudragit® FS 30D suspension is commenced, maintaining a product temperature of 28° C.-32° C. and atomization air pressure of 3 bar. At the end of coating, the tablets are discharged and placed in a circulating air oven to dry at 40° C. for 2 hours. Similarly, other enteric coatings such as Eudragit® L, S, ethylcellulose, HPMCAS, PVAP, CAP, CAS, etc. may be utilized to form delayed release tablets at various weight gains.
[0141] Example 3 Delayed release compositions comprising linaclotide Delayed release capsules containing linaclotide can be formulated to target the ileum or colon. The compositions are formulated to include pH-triggered release based on enteric coating of linaclotide tablets, capsules, or linaclotide-coated beads contained in hard gelatin capsules. The compositions may be further formulated to include stabilizing additives such as divalent cations and amino acids. PVA can be used not only as a binder but also as a protective layer between linaclotide and the enteric coating. Linaclotide or linaclotide with a PVA overcoat (as beads, capsules, or tablets) may be coated with an additional enteric coating (e.g., Eudragit® FS30D, Eudragit® S100, Eudragit® L100, Eudragit® L100-55, Eudragit® L 30D-55) that dissolves in a pH-dependent manner to release at the correct pH of 7 in the ileum of the GI tract. The enteric coating may consist of a blend combining different types of Eudragit® - Eudragit® S100 / Eudragit® L100 in different ratios (e.g. 50 / 50 ratio); Eudragit® S100 / Eudragit® L100-55 in various ratios; Eudragit® FS30D / Eudragit® L 30D-55, Eudragit® FS30D / Eudragit® S / Eudragit® RS or EC in various ratios. The composition may further comprise other excipients including plasticizers such as triethyl citrate. The coating may further comprise a disintegrant as a suspended solid to promote a relevant pH-triggered release, resulting in a mixed system as croscarmellose sodium / Eudragit® S. For ease of processing, anti-blocking agents (eg, talc, Aerosil® 200 or PlasAcryl™) can be used to prevent the beads from sticking.
[0142] Additionally, two Eudragit® coatings can be utilized to ensure rapid release upon reaching the desired pH region of the GI tract, including a partially neutralized coating system. One of the two Eudragit® films can include a buffer such as potassium hydrogen phosphate. Alternative non-Eudragit® pH-dependent film coatings include hydroxypropyl methylcellulose acetate succinate (HPMCAS, e.g., Aqoat® AS-HF), cellulose acetate phthalate (CAP, e.g., Aquateric®), or shellac.
[0143] Example 4 Determination of content and purity of representative peptides Linaclotide, immdidazolidinone decomposition products ("Cys 1 -IMD"), and α-ketone degradation products ("Cys 1 Linaclotide content and purity can be measured and purified as described in US2010 / 0048489, US2013 / 0190238, and US2015 / 0094272, which are incorporated herein by reference. Generally, linaclotide content and purity can be measured and purified as described in ChemstationRev A.09. The concentration can be determined by reversed-phase gradient liquid chromatography using an Agilent Series 1100 LC System equipped with 03 software or equivalent. A YMC Pro™ C18 column (dimensions: 3.0×150 mm, 3.5 um, 120 Å; Waters Corp, Milford, MA) or equivalent is maintained at 40° C. Mobile phase A (MPA) consists of water with 0.1% trifluoroacetic acid, and mobile phase B (MPB) consists of 95% acetonitrile:5% water with 0.1% trifluoroacetic acid. Elution of linaclotide is achieved by a gradient of 0% to 47% MPB in 28 minutes followed by a gradient to 100% MPB in 4 minutes, held at 100% MPB for 5 minutes to wash the column. The column is re-equilibrated by returning to 0% MPB in 1 minute followed by a 100% MPA hold for 10 minutes. The flow rate is 0.6 mL / min with UV detection at 220 nm.
[0144] Example 5 In vitro drug release testing Linaclotide release from coated tablets can be evaluated in dissolution tests using a USP XXIV Type II paddle dissolution apparatus (model PTWS, Pharma Test, Hainburg, Germany). Tests are performed in triplicate with a paddle speed of 100 rpm in 900 ml of dissolution medium maintained at 37.0±0.5°C. Tablets are first tested for 30 minutes or 2 hours in 0.1 N hydrochloric acid (pH 1.2) to simulate gastric retention, and then for 6 hours in buffer media of various pH and ionic composition similar to the pH conditions of the small intestine. Linaclotide release can be evaluated in two official buffer media, namely 0.067 M mixed sodium and potassium phosphate (Sorensen) buffer and 0.05 M potassium phosphate buffer at pH 6.8-7.4, as well as in a multielectrolyte salt solution (Hanks) buffer at pH 7.4, whose ionic composition resembles intestinal fluids. All buffers are prepared fresh with deionized water and degassed by sparging with helium prior to use. The amount of linaclotide released from the dosage form can be determined by reverse-phase gradient liquid chromatography as described in Example 4.
[0145] Example 6 Release profile of linaclotide tablets The release profiles of linaclotide tablets were tested at various pH for three delayed release formulations. Sample 181-64B contains a 100 μg dose of linaclotide, a subcoat of Opadry II, and a functional coat of Eudragit FS 30D and talc. Sample 181-64C contains a 100 μg dose of linaclotide, a subcoat of Opadry II, and a functional coat of Eudragit FS 30D and Eudragit PlasAcryl™. The release profiles for lot 181-64B and lot 181-64C are provided in FIG. 1.
[0146] Example 7 Preparation of Linaclotide Tablets A delayed release tablet can be prepared by first preparing the following core tablet ingredients: placebo base, linaclotide 750 μg / 225 mg base, and pregranulated filler.
[0147] Granule manufacturing process: Tablet ingredients can be prepared in separate granulations for blending before tablet compression. The use of separate tablet ingredients, such as placebo base and pre-granulation filler base, provided advantageous properties, among others, for tablet stability and release profile. For example, all tablet ingredients listed in Table 2 could be prepared separately by wet granulation and blended or blended together before compression and processed as a mixture for wet granulation. In another process, all tablet ingredients listed in Table 2 could be prepared separately by dry granulation and blended or blended together before compression and processed as a mixture for dry granulation. In another process, tablet ingredients are directly blended for compression. In a preferred process, pre-granulation filler base and / or placebo base are prepared via wet granulation and mixed with 750 μg / 225 mg linaclotide base after drying. Linaclotide base could be prepared by wet granulation process or by Wurster coating process. This preferred process demonstrated further increased tablet stability by reducing moisture exposure to linaclotide during processing and minimizing residual moisture in the tablet core.
[0148] [Table 2]
[0149] The blend is then compressed in a suitable tablet press targeting a core tablet weight of 225 mg. A subcoat (OPADRY® II) is applied in a perforated pan coater at a weight gain of 4% w / w. Coating conditions should be set and monitored such that moisture uptake during coating is kept to a minimum. As measured by loss on drying (LOD), the subcoated tablets should have an LOD of 1.5% or less. A functional coat is applied over the subcoated tablets in a perforated pan coater. The functional coat is either Eudragit® FS30D, Eudragit® S100, or Eudragit® L100. 5 mg polymer weight / cm 2(tablet area). This results in a total polymer weight gain of approximately 4.5% during functional coating. Coating conditions should be set and monitored such that moisture uptake during coating is kept to a minimum. As measured by loss on drying, functional coated tablets should have an LOD of 2.0% or less.
[0150] Placebo vehicle preparation: Table 3 shows the placebo base granulation formulation. [Table 3]
[0151] A placebo base formulation may be prepared by first blending the ingredients in Table 4. [Table 4]
[0152] Weigh the mixing vessel and add 2682.1±5.0 g of process water to the vessel. Set the mixer and begin stirring the water. Add EMPROVE® to the water while stirring and start the timer. Cover the solution and heat to 70° C. while stirring, maintaining the temperature until the material is visibly dissolved.
[0153] Adjust the pH of the solution to 1.5 with hydrochloric acid. Add calcium chloride dihydrate to the solution while stirring. Mix until dissolved. Add L-histidine to the solution while stirring. Stir for approximately 15 minutes. Record this initial pH. Adjust the pH of the solution to 5.0 with hydrochloric acid. Record the final pH of the solution and the hydrochloric acid addition. Mix until all materials are dissolved. Adjust the pH of the solution to 2.5 with hydrochloric acid while mixing. Record the final pH of the solution and the hydrochloric acid addition. Ensure high shear granulator is correctly set up for granulation with a 25 L bowl, mixing impeller and chopper. Place microcrystalline cellulose into the granulator bowl through a 16 mesh screen. Calculate the net weight of granulation solution to be added. Pump the granulation solution into the granulator at a rate of approximately 300 g / min while mixing with the following parameters: impeller speed 1 (290 rpm, tip speed of 5.5 m / sec), chopper speed 1 (1760 rpm). Stop the granulator and scrape the sides and bottom of the bowl. Mix for an additional 3 minutes with the following parameters: Impeller speed 1 (290 rpm, tip speed of 5.5 m / sec), Chopper speed 1 (1760 rpm). Weigh a polybag and discharge the finished wet granulation into it. Weigh the granulation. Transfer the wet granulation to the FLM-3 fluid bed for drying. Dry the granulation using the following approximate settings: Dry until the granulation LOD is 1.2% moisture or less. Discharge the dry granulation into a weighed polybag.
[0154] [ka] Settings are only recommended settings and may be adjusted for optimum drying.
[0155] Sift the dry granulation through a #30 mesh sieve. Weigh a polybag and dump the dry granulation into it. Weigh the granulation. Package the dry granulation in foil sealed bags with desiccant.
[0156] Preparation of linaclotide base (i.e., 750 μg / 225 mg): Table 5 shows the formulation for a 750 μg / 225 mg base granulation. [Table 5]
[0157] A 750 μg / 225 mg base granulation can be prepared by first mixing the ingredients in Table 6. [Table 6]
[0158] Add linaclotide to granulation solution while mixing. Mix until dissolved. Ensure high shear granulator is properly set up for granulation using 25 L bowl, mixing impeller and chopper. Place microcrystalline cellulose through a 16 mesh screen into granulator bowl. Pump granulation solution into granulator at a rate of approximately 300 g / min while mixing with the following parameters: impeller speed 1 (290 rpm, tip speed of 5.5 m / sec), chopper speed 1 (1760 rpm). Weigh polybag and discharge finished wet granulation into it. Weigh granulation. Transfer wet granulation to fluid bed for drying. Dry granulation using the following approximate settings: Dry until granulation LOD is 1.2% moisture or less. Discharge dry granulation into weighed polybag.
[0159] [ka] Note: Settings are only recommended settings and may be adjusted for optimal drying.
[0160] Sift the dry granulation through a #30 mesh sieve. Weigh a polybag and dump the dry granulation into it. Weigh the granulation. Package the dry granulation in foil sealed bags with desiccant.
[0161] Preparation of pre-granulated filler: Table 7 presents the formulation for the pregranulated filler. [Table 7]
[0162] The filler formulation can be prepared by first blending the ingredients in Table 8. [Table 8]
[0163] Next, record the tare weight of the stainless steel container. Weigh the container and weigh the required amount of process water into the container. Transfer the water to the jacketed kettle. Set the mixer to begin stirring the water in the kettle. Add EMPROVE® (polyvinyl alcohol) to the water while stirring and start the timer. Cover the solution and heat to 70°C while stirring, maintaining the temperature until the ingredients are visibly dissolved. Calculate the water loss due to evaporation during heating. Add this amount of process water to the solution. Add the microcrystalline cellulose, croscarmellose sodium, and mannitol to the bowl of the high shear granulator, respectively. Mix for approximately 2 minutes according to the following parameters: impeller speed 1 (290 rpm, tip speed of 5.5 m / sec), chopper speed 1 (1760 rpm). Pump 2217±5 g of granulation solution into the granulator at a rate of approximately 300 g / min while mixing with the following parameters: impeller speed 1 (290 rpm, 5.5 m / sec tip speed), chopper speed 1 (1760 rpm). Stop the granulator and scrape the sides and bottom of the bowl. Mix for an additional 30 seconds to 1 minute with the following parameters: impeller speed 1 (290 rpm, 5.5 m / sec tip speed), chopper speed 1 (1760 rpm). Weigh a polybag and discharge the finished wet granulation into it. Weigh the granulation. Pass the wet granulation through a Comil equipped with a 2A375Q03763 screen at 5-10% power. Transfer the wet granulation to an FLM-3 fluid bed for drying. Dry the granulation using the following approximate settings: Dry until the granulation LOD is 1.0% moisture or less. Discharge the dry granulation into a weighed polybag.
[0164] [ka] Settings are only recommended settings and may be adjusted for optimum drying.
[0165] Mill the granulation using Comil, round impeller, 2A045R03137 screen. Weigh a polybag and dump the dry and milled granulation into it. Weigh the granulation. Package the dry granulation in foil sealed bags with desiccant.
[0166] Example 8 Blending and Compression of 25μg Tablets Following the procedure of Example 13, 25 μg dose tablets of linaclotide can be prepared with the formulation in Table 9. [Table 9]
[0167] First, prepare the ingredients in Table 10. [Table 10]
[0168] Preblend: Place an 8 qt blender and add 750 μg / 225 mg base and placebo base. Close lid and blend for 10 minutes. Weigh polybag and drain preblend into it.
[0169] Subblend A: Add 650g of preblend to 16qtv-blender. Add pregranulated filler for Subblend A to 16qtv-blender. Close lid and blend for 10 minutes. Pass magnesium stearate for Subblend A through a 40 mesh screen. Add to 16qtv-blender. Close lid and blend for 3 minutes. Drain blend into weighed polybag.
[0170] Subblend B: Add 650g of preblend to a 16qtv-blender. Add pregranulated filler for Subblend B to a 16qtv-blender. Close lid and blend for 10 minutes. Pass magnesium stearate for Subblend B through a 40 mesh screen. Add to a 16qtv-blender. Close lid and blend for 3 minutes. Drain blend into weighed polybag.
[0171] Compression: Ensure that the Korsch XL100 tablet press with 0.32" sc tooling is installed with 0.32" concave tooling (10 stations preferred), paddle feeder and ensure all other components are properly secured. Manually rotate the die table at least one full rotation to ensure proper installation. Visually verify that all dies and punches are present and that dies are flush with the die table. Verify that tablet specifications meet the in-process tablet specifications in Table 11.
[0172] [Table 11]
[0173] Load the blend into the hopper. Set the turret speed to the appropriate speed. Adjust the die fill and compression parameters to obtain tablets with a target weight of 225 mg and a target hardness of 8-12 kP. All waste should be collected in a tableting waste polybag. Start the timer to compress the tablets.
[0174] Example 9 Blending and Compression of 100μg Tablets Following the procedure of Example 7, 100 μg dose tablets of linaclotide can be prepared with the formulation in Table 12. [Table 12]
[0175] First, prepare the ingredients in Table 13. [Table 13]
[0176] Preblend: Place a 16 qt blender and add 750 μg / 225 mg base and placebo base. Close lid and blend for 10 minutes. Weigh polybag and drain preblend into it.
[0177] Add 2500 g of preblend to a 1 cubic foot v-blender. Add pregranulated filler to a 1 cubic foot v-blender. Close lid and blend for 10 minutes. Pass magnesium stearate through a 40 mesh screen. Add to a 1 cubic foot v-blender. Close lid and blend for 3 minutes. Drain blend into weighed polybag.
[0178] Compression: Ensure that the Korsch XL100 tablet press with 0.32" sc tooling is installed with 0.32" concave tooling (10 stations preferred), paddle feeder and ensure all other components are properly secured. Manually rotate the die table at least one full rotation to ensure proper installation. Visually verify that all dies and punches are present and that the dies are flush with the die table. Verify that the tablet specifications meet the in-process tablet specifications in Table 14.
[0179] [Table 14]
[0180] Load the blend into the hopper. Set the turret speed to the appropriate speed. Adjust the die fill and compression parameters to obtain tablets with a target weight of 225 mg and a target hardness of 8-12 kP. All waste should be collected in a tableting waste polybag. Start the timer to compress the tablets.
[0181] Example 10 Blending and Compression of 290μg Tablets Following the procedure of Example 7, 290 μg dose tablets of linaclotide can be prepared with the formulation in Table 15. [Table 15]
[0182] First, prepare the ingredients in Table 16. [Table 16]
[0183] Subblend A: Add pregranulation filler and linaclotide base for Subblend A to a 16 qtv-blender. Close lid and blend for 10 minutes. Pass magnesium stearate for Subblend A through a 40 mesh screen. Add to a 16 qtv-blender. Close lid and blend for 3 minutes. Weigh and discharge blend into a polybag.
[0184] Subblend B: Add pregranulation filler and linaclotide base for Subblend B to a 16 qtv-blender. Close lid and blend for 10 minutes. Pass magnesium stearate for Subblend B through a 40 mesh screen. Add to a 16 qtv-blender. Close lid and blend for 3 minutes. Weigh and discharge blend into a polybag.
[0185] Compression: Ensure that the Korsch XL100 tablet press with 0.32" sc tooling is installed with 0.32" concave tooling (10 stations preferred), paddle feeder and all other components are properly secured. Manually rotate the die table at least one full rotation to ensure proper installation. Visually verify that all dies and punches are present and that the dies are flush with the die table. Verify that the tablet specifications meet the in-process tablet specifications in Table 17.
[0186] [Table 17]
[0187] Load the blend into the hopper. Set the turret speed to the appropriate speed. Adjust the die fill and compression parameters to obtain tablets with a target weight of 225 mg and a target hardness of 8-12 kP. All waste should be collected in a tableting waste polybag. Start the timer to compress the tablets.
[0188] Example 11 Subcoating of linaclotide 25μg tablets The 25 μg tablets of Example 14 can be subcoated with an Opadry® II subcoat. The formulation in Table 18 represents the amount of coating material required to prepare, with an overpreparation to account for losses during the coating process. [Table 18]
[0189] Dispense 1600 g of purified water into an appropriately sized container. Dispense 400 g of Opadry® II into an appropriately sized container. Add Opadry® to the water. Calculate the theoretical amount of solution needed to give a 4.0% weight gain at a theoretical efficiency of 85%. Prepare a poly bag for waste tablets that will be collected during the coating process. Ensure the Compu-Lab is equipped with a 19 inch pan and plenum assembly. Ensure the liquid supply line is Tygon 17 tubing. Ensure the gun assembly is attached to the pan. The spray gun assembly is a 1x 100mm nozzle with a 40100 AB liquid spray nozzle and matching air cap. 1The coating machine should consist of a 1 / 4JAU spray gun. The gun assembly should be mounted as far away from the tablet bed as possible with a perpendicular spray angle in the top third of the bed. Verify initial tablet weight by weighing 100 uncoated tablets. Divide tablet weight by 100 to calculate average single tablet weight. Check initial tablet moisture by crushing approximately 1 gram tablets and following LOD at 105°C for 10 minutes. Adjust pump for liquid flow rate of approximately 10g / min. Prime lines through gun and ensure there are no leaks in lines or gun. Load tablets into coating pan and begin warm up for 20 minutes with inlet temperature of 50°C and air flow of 350 CFM. Rock occasionally during warm up.
[0190] Once the target bed temperature is reached, begin spraying the coating suspension according to the target process parameters outlined in Table 19 below. Check and report tablet moisture content periodically, if desired. Check tablets for weight gain once the theoretical amount of solution has been added. When a 4% weight gain is reached, stop spraying and dry the tablets for 30 minutes at an inlet temperature of 50° C. while reducing the pan speed to minimum or fine. Discharge the tablets and determine the new weight of the coated tablets.
[0191] [Table 19]
[0192] Example 12 Subcoating of 100 μg linaclotide tablets The 100 μg tablets of Example 15 can be subcoated with an Opadry® II coating. The formulation in Table 20 represents the amount of coating material required to be prepared with an overpreparation to account for losses during the coating process. [Table 20]
[0193] Dispense 4000 g of purified water into an appropriately sized container. Dispense 1000 g of Opadry® II into an appropriately sized container. Add Opadry® to the water. Calculate the theoretical amount of solution needed to give a 4.0% weight gain at 85% theoretical efficiency. Ensure the Compu-Lab is equipped with a 24 inch pan and plenum assembly. Ensure the fluid supply line is Tygon 17 tubing. Ensure the gun assembly is attached to the pan. The spray gun assembly is a 2x 1000 psi ... 1 The coating machine should consist of a 1 / 4JAU spray gun. The gun assembly should be mounted as far away from the tablet bed as possible with a perpendicular spray angle in the top third of the bed. Verify initial tablet weight by weighing 100 uncoated tablets. Divide tablet weight by 100 to calculate average single tablet weight. Check initial tablet moisture by crushing approximately 1 gram tablets and following LOD at 105°C for 10 minutes. Adjust pump for liquid flow rate of approximately 20g / min. Prime lines through gun and ensure there are no leaks in lines or gun. Load tablets into coating pan and begin warm up for 20 minutes with inlet temperature of 50°C and air flow of 400 CFM. Rock occasionally during warm up.
[0194] Once the target bed temperature is reached, begin spraying the coating suspension according to the target process parameters outlined in Table 21 below. Check and report tablet moisture content periodically, if desired. Check tablets for weight gain once the theoretical amount of solution has been added. When a 4% weight gain is reached, stop spraying and dry the tablets for 30 minutes at an inlet temperature of 50° C. while reducing the pan speed to minimum or fine. Discharge the tablets and determine the new weight of the coated tablets.
[0195] [Table 21]
[0196] Example 13 Subcoating of 290μg Linaclotide Tablets The 290 μg tablets of Example 16 can be subcoated with an Opadry® II coating. The formulation in Table 22 represents the amount of coating material required to be prepared with an overpreparation to account for losses during the coating process. [Table 22]
[0197] Dispense 1600 g of purified water into an appropriately sized container. Dispense 400 g of Opadry® II into an appropriately sized container. Add Opadry® to the water. Calculate the theoretical amount of solution needed to give a 4.0% weight gain at 85% theoretical efficiency. Ensure the Compu-Lab is equipped with a 19 inch pan and plenum assembly. Ensure the fluid supply line is Tygon 17 tubing. Ensure the gun assembly is attached to the pan. The spray gun assembly is a 1x 100mm nozzle with a 40100 AB fluid spray nozzle and matching air cap. 1 The coating machine should consist of a 1 / 4JAU spray gun. The gun assembly should be mounted as far away from the tablet bed as possible with a perpendicular spray angle in the top third of the bed. Verify initial tablet weight by weighing 100 uncoated tablets. Divide tablet weight by 100 to calculate average single tablet weight. Check initial tablet moisture by crushing approximately 1 gram tablets and following LOD at 105°C for 10 minutes. Adjust pump for liquid flow rate of approximately 10g / min. Prime lines through gun and ensure there are no leaks in lines or gun. Load tablets into coating pan and begin warm up for 20 minutes with inlet temperature of 50°C and air flow of 350 CFM. Rock occasionally during warm up.
[0198] Once the target bed temperature is reached, begin spraying the coating suspension according to the target process parameters outlined in Table 23 below. Check and report tablet moisture content periodically, if desired. Check tablets for weight gain once the theoretical amount of solution has been added. When a 4% weight gain is reached, stop spraying and dry the tablets for 30 minutes at an inlet temperature of 50° C. while reducing the pan speed to minimum or fine. Discharge the tablets and determine the new weight of the coated tablets.
[0199] [Table 23]
[0200] Example 14 Functional or enteric coating of linaclotide tablets The tablets of the previous examples can be prepared with a functional coating. The formulations in Table 24 represent the amount of coating material required to be prepared in excess to account for losses during the coating process. [Table 24]
[0201] To prepare the functional coating, dispense the required amount of Eudragit® S100 and Eudragit® L100 into an appropriately sized container. Dispense ⅔ of the required amount of purified water into an appropriately sized container. Begin stirring the water until a vortex is achieved. Slowly add Eudragit® S100 and Eudragit® L100 to the water and mix until the powders are completely wetted and any lump or bubble formation has dissipated (approximately 5 minutes).
[0202] Dispense the required amount of 1N NH3 into an appropriately sized container. Slowly add the 1N NH3 to the Eudragit® suspension and mix for a minimum of 60 minutes. Dispense the required amount of triethyl citrate into an appropriately sized container. Add the triethyl citrate to the Eudragit® suspension and mix for a minimum of 60 minutes. Dispense the required amount of talc into an appropriately sized container. Homogenize the talc in the remaining ⅓ purified water using a Silverson Homogenizer for 10 minutes (or until homogenous). Pour the talc suspension into the Eudragit® suspension while mixing. Mix for less than 5 minutes. Screen the coating suspension through a #30 mesh screen.
[0203] Calculate the theoretical amount of solution needed to give a 9.0% weight gain at 90% theoretical efficiency. Ensure the Compu-Lab is equipped with a 19 inch pan and plenum assembly. Ensure the fluid supply line is Tygon 17 tubing. Ensure the gun assembly is attached to the pan. The spray gun assembly is a 1x 40100 AB fluid spray nozzle and matching air cap. 1 The coating system should consist of a 1 / 4JAU spray gun. The gun assembly should be mounted as far away from the tablet bed as possible with a perpendicular spray angle in the upper third of the bed. Load the tablets into the coating pan. Warm the tablets at an inlet temperature of 30 degrees. Ensure that the bed temperature reaches approximately 30 degrees before proceeding. Adjust the pump to give a fluid flow rate of approximately 12g / min. Prime the lines through the gun and ensure there are no leaks in the lines or gun. Check the starting tablet moisture by crushing approximately 2 grams of tablets and chasing the LOD at 105°C for 10 minutes.
[0204] Once the target bed temperature is reached, begin spraying the coating suspension according to the target process parameters outlined in Table 25 below. Check and report tablet moisture content periodically, if desired. Once the theoretical amount of solution has been added, check the tablets for weight gain. When a 9% weight gain is reached, stop spraying and dry the tablets for 5-10 minutes at an inlet temperature of 40°C with the pan speed reduced to minimum or fine.
[0205] [Table 25]
[0206] Check final tablet moisture by crushing approximately 2 grams of tablets and following the LOD at 105°C for 10 minutes. Moisture should be ≦initial tablet moisture. Discharge tablets and determine new weight of coated tablets. Dry tablets for at least 2 hours in a mechanical convection oven set at 40°C. Bulk package tablets in foil bags with desiccant and store at 5°C.
[0207] Example 15 Organic coating of linaclotide tablets The linaclotide tablets of the above examples may be provided with an organic coating. For coating the 100 μg tablets, the formulation in Table 26 was used. [Table 26]
[0208] Dispense the required amount of purified water into an appropriately sized container. Dispense the required amount of acetone into an appropriately sized container. Begin mixing the acetone and add the water. Dispense the required amount of isopropanol into an appropriately sized container. Add the isopropanol to the water and acetone to create a diluent mixture. Pour approximately half of the diluent mixture into the second solution and begin mixing the first half of the diluent mixture again. Dispense the required amount of Eudragit® S100 into an appropriately sized container. Begin mixing the second half of the diluent mixture and add the Eudragit® S100. Dispense the required amount of Eudragit® L100 into an appropriately sized container.
[0209] Add Eudragit® L100 to the diluent mixture containing Eudragit® S100 and start a timer. Stir until the polymer is completely dissolved. Add triethyl citrate to the first half of the diluent mixture while mixing with a high shear mixer. Dispense the required amount of talc into an appropriately sized container. Add the talc to the first half of the diluent mixture while mixing with a high shear mixer to create an excipient suspension. Start a timer and mix for at least 10 minutes. Record the mixing time of the Eudragit solution. While continuing to mix the Eudragit solution, slowly pour the excipient suspension into the Eudragit solution. Once the coating suspension is uniform, pass it through a 35 mesh screen. Resume mixing. Calculate the theoretical amount of solution needed to give a weight gain of 8.5% at a theoretical efficiency of 88%.
[0210] Prepare a poly bag for waste tablets that will be collected during the coating process. Ensure the Compu-Lab is equipped with a 15 inch pan and plenum assembly. Ensure the fluid supply lines are solvent resistant 17 tubing. Ensure the gun assembly is attached to the pan. The spray gun assembly is equipped with a 1x 40100 AB fluid spray nozzle and matching air cap. 1 The coating process should consist of a 1 / 4JAU spray gun. The gun assembly should be mounted as far away from the tablet bed as possible with a spray angle perpendicular to the top third of the bed. Adjust the pump so that the liquid flow rate is approximately 28g / min. Prime the line through the gun and ensure there are no leaks in the line or gun. Load the tablets into the coating pan and begin warming with an inlet temperature of 38°C and 200 CFM air flow. Rock occasionally during warm-up. Once the product temperature reaches approximately 27°C, begin spraying the coating suspension according to the target process parameters outlined below. When an 8.5% weight gain is reached, stop spraying and dry the tablets for 10 minutes at an inlet temperature of 40°C with the pan speed reduced to minimum or fine.
[0211] [ka]
[0212] The tablets are dried on trays in a mechanical convection oven set at 45° C. for at least 24 hours.
[0213] Example 16 Efficacy of linaclotide in an animal model of overactive bladder / interstitial cystitis The objective of this non-clinical non-GLP study was to investigate the mechanisms underlying TNBS-induced bladder hyperactivity and the ability of linaclotide to reduce TNBS-induced changes in bladder function by:
[0214] Objective To determine changes in the mechanical sensitivity of bladder afferents in chronic visceral hypersensitivity (CVH) mice compared with healthy mice.
[0215] To examine changes in chemosensitivity of bladder afferent nerves and detrusor smooth muscle from healthy and CVH mice to exogenous agonists, including an acetylcholine receptor agonist (carbachol), a purinergic receptor agonist (αβMe-ATP), and a TRPV1 agonist (capsaicin).
[0216] To determine the excitability of bladder DRG neurons traced retrogradely from both thoracic and lumbar regions in healthy and CVH mice.To determine the effect of chronic administration of linaclotide once daily for 2 weeks on the excitability of bladder DRG neurons traced retrogradely from both thoracic and lumbar regions.
[0217] The TNBS model used in this study has been previously described and demonstrated to induce chronic visceral hypersensitivity (CVH) to mechanical stimulation of colonic afferent nerves 28 days after TNBS administration (Hughes et al., (2009) Gut, 58:1333-41.; Castro et al., (2013) Gastroenterology, 145:1334-1346, each of which is incorporated herein by reference in its entirety).
[0218] animal C57 / BL6 mice were provided by SAHMRI Bioresources following our standard practice. Mice were initially group-housed under a standard light / dark cycle with free access to water and standard diet. Mice were individually housed for the duration of the 28-day experiment. Healthy mice: male C57 / BL6 mice, aged 13-17 weeks.
[0219] Induction of colitis (TNBS-recovered chronic visceral hypersensitivity (CVH) mice): Male C57 BL / 6 mice were used in all experiments. Colitis was induced by administration of TNBS as previously described (Brierley et al., 2002, incorporated herein by reference in its entirety). al., (2011) J. Physiol, 15:3575-3593). Briefly, 13-week-old mice were administered 0.1 mL of TNBS (130 μg / mL in 30% EtOH) by intracolonic enema via a polyethylene catheter inserted 3 cm from the anus of isoflurane-anesthetized mice. Mice were then individually housed and observed daily for changes in body weight, physical appearance, and behavior. Histological examination of mucosal architecture, cellular infiltrates, crypt abscesses, and goblet cell depletion demonstrated that the significant TNBS-induced damage by 3 days after treatment was largely reversed by 7 days and completely reversed at 28 days (Brierley et al., (2008) Gastroenterology, 134:2059-69, incorporated herein by reference). High-threshold nociceptors from mice at 28 days exhibited significant mechanical hypersensitivity, lower mechanical activation thresholds, and exhibited hyperalgesia and allodynia. As such, they are therefore referred to as "chronic visceral hypersensitivity" (CVH) mice.
[0220] Ex vivo afferent nerve recordings from bladder-pelvic afferents Pelvic bladder afferents are classified by their ability to respond to ramp bladder distention. During bladder distention, there is an increase in intravesical pressure and corresponding afferent neuronal activity. The mechanical sensitivity of these afferents was tested by ramp distention to a final intravesical pressure of 30 mmHg in bladder preparations from healthy and CVH mice as well as from CVH mice that had received once daily oral gavage of vehicle or linaclotide (3 μg / kg / day) for 2 weeks.
[0221] Recordings were made from healthy and CVH mice that were chronically administered vehicle or linaclotide (3 μg / kg / day) for a total duration of up to 2 weeks and euthanized by CO2 inhalation and cervical dislocation. Animals were cut in two at the level of L2, eliminating vascular communication by the aorta and vena cava, but ensuring that the kidneys and ureters remained intact. The tail and hind limbs were removed, and the remaining pelvic section consisting of the bladder, testes, urethra, ureters, and kidneys was placed in ice-cold Krebs solution and transported to the recording chamber. The recording chamber was continuously perfused with oxygenated (95% O2 and 5% CO2) Krebs bicarbonate solution (composition, in mM: NaCl 118.4, NaHCO3 24.9, CaCl2 1.9, MgSO4 1.2, KH2PO4 1.2, glucose 11.7) at a stable temperature of 35 °C to maintain functional tissue.
[0222] Under a dissecting microscope (WPI, PZMIII), the ureter was identified and silk suture (US 4 / 0) was used to prevent reflux. Excess tissue around the bladder neck was removed to expose the pubic symphysis. The pubic symphysis was cut along the rostral / caudal axis of the urethra and the connective tissue attaching them together was removed. The pelvic bones on either side of the urethra were cut to their attachment to the hind limbs to improve visibility and facilitate dissection of the pelvic nerve. The terminal urethra was cut and a catheter (OD 0.03IN) attached to a syringe pump (Genie, Kent, multi-phaser™ model NE-1000) was inserted into the bladder and tied in place with silk suture. The bladder was then filled with 0.9% saline to create a small amount of pressure in order to puncture the bladder dome with a needle (BD microlance™, 19G 2 inch). A dual lumen catheter connected to both pressure transducers (DTX™ plus DT-XX, Becton Dickinson, Singapore) was then inserted through the incision into the bladder dome and secured in place with silk sutures to allow recording of intravesical pressure and outflow (2-way) taps, which allowed control of bladder filling and emptying by opening and closing the taps.
[0223] After catheter placement, the bladder nerve fascicles, containing both pelvic and hypogastric afferents exiting the bladder, were located around the base of the bladder proximal to the point where they connect the base to the urethra. As they extend dorsally towards the spinal cord, they converge with the urethral fascicles, where they are most easily identified under the microscope. Gently remove connective and adipose tissue to expose the nerve fascicles, which were carefully divided into individual fibers. Nerve fibers were selected and inserted into a suction electrode (tip diameter 25-50 μm) attached to a Neurolog headstage (NL100, digitimer, Ltd, UK), which allows for the recording of multiunit afferent nerve activity. After connecting the NL100 to an AC preamplifier (NL014) that allows amplification of the nerve signal (10,000 times), the nerve signal was filtered (NL125, band pass filter), passed through a 50 / 60Hz electrical noise eliminator (Humbug, Quest Scientific) and finally passed through a micro1401 similar to digital interface and visualized on a computer using Spike2 software (version 7.1, Cambridge Electronic Design, UK). Mechanical sensitivity is measured as the number of action potentials passing a preset threshold for a given pressure. The number of action potentials per second bin can be converted into a rate histogram and the total values for the number of action potentials / second can be plotted against the pressure.
[0224] Bladder contraction / relaxation experiments and exogenous chemical stimulation of bladder muscle Bladder afferent chemosensitivity was also tested after isolation of the pelvic afferents and catheterization of the bladder. After an equilibration period, when the bladder afferent response to ramp distention had stabilized, the bladder was inflated to a physiological pressure of 6 mmHg above baseline. At this point, saline perfusion was stopped but the outflow tap remained closed to maintain bladder volume. The bladder was maintained in this state for 45 minutes to accommodate the increase in volume, during which time baseline intravesical pressure and afferent excitation stabilized.
[0225] After an equilibration period, bath perfusion is briefly stopped to administer bolus doses of agonists: carbachol (1 μM), αβMe-ATP (30 μM), and capsaicin (10 μM) are administered consecutively with a 1-hour washout period between each dose.
[0226] Chemosensitive responses were measured as the number of action potentials exceeding a preset threshold at a given time after agonist administration. Intravesical pressure was determined as the change from baseline pressure at a given time after agonist administration.
[0227] Retrograde tracing of bladder DRG neurons. Laparotomy was performed on anesthetized (2-3% isofluorane / 0.3 L / min O2) mice. AlexaFluor 488-conjugated Cholera Toxin Subunit B (5ug / ul in 10ul of sterile PBS; ThermoFisher product no. C22842 (formerly LifeTechnologies)) was used for subserosal injection (2-3ul per injection) in the descending colon or dorsolateral bladder using a 30G Hamilton needle. The incision was closed with Prolene 6 / 0 suture (Johnson&Johnson product no. 8636G). All mice were given 100ul of buprenorphine (1:12) and Baytril (1:20) for post-operative care and left for 4 days before being allowed to rest for DRG cell culture.
[0228] Patch clamp recordings from retrogradely traced bladder DRG neurons Recordings were made from healthy and CVH mice. CVH mice received chronic administration of vehicle or linaclotide (3 μg / kg / day) for a total duration of 2 weeks. Mice were euthanized by CO2 inhalation and DRGs were removed from the thoracic-lumbar (T10-L1) and lumbosacral (L6-S1) regions and digested with 3 mg mL-1 collagenase II (Gibco) and 4 mg mL-1 dispase (Gibco) for 30 min at 37 °C, followed by digestion with 3 mg mL-1 collagenase II alone for 10 min at 37 °C. Neurons were mechanically dissociated into single-cell suspensions via trituration with a fire-polished Pasteur pipette. Neurons were resuspended in Dulbecco's modified Eagle's medium (DMEM; Gibco) containing 10% fetal calf serum (FCS; Invitrogen), 2 mM L-glutamine (Gibco), 100 uM minimum essential medium (MEM), nonessential amino acids (Gibco), and 100 mg mL-1 penicillin-streptomycin (Invitrogen). Nerve growth factor (NGF) was also included at 100 ng mL-1 (Sigma-Aldrich). Neurons were spotted onto 8 mm HCl-treated coverslips coated with poly-D-lysine (800 μg mL-1) and laminin (20 μg mL-1) and maintained at 37 °C in 5% CO2 for 48 h.
[0229] Recordings were made similarly to those described previously (Brierley et al., 2011, supra). Briefly, whole-cell patch-clamp recordings were made from thoracic-lumbar (T10-L1) or lumbosacral (L6-S1) DRG neurons. This demonstrated fluorescence following retrograde tracer (CTB-AF488) injection into the bladder wall, 48 h after application, using fire-polished glass electrodes with resistances of 5–7 MΩ. All recordings were made at room temperature (20–22 °C). Signals were amplified using an Axopatch 200A amplifier, digitized with a Digidata 1322A, and recorded using pCLAMP 9 software (Molecular Devices, Sunnyvale, CA, USA). For all neurons, the baseline holding potential was −70 mV. The intracellular solution contained (in mM): KCl, 135; MgCl2, 2; MgATP, 2; EGTA-Na, 5; Hepes-Na, 10; pH adjusted to 7.4. The extracellular solution contained (in mM): NaCl, 140; KCl, 4; MgCl2, 2; CaCl2, 2; Hepes-Na, 10; glucose, 5; pH adjusted to 7.4. For current clamp studies, a series of depolarizing pulses (500 ms, 10 pA steps) were applied from a holding potential (65 mV) to determine the rheobase (or the amount of current (pA) required to generate an action potential). The number of action potentials at the rheobase and 2×rheobase were also determined, and the resting membrane potential was recorded. These measurements were performed in normal extracellular solution.
[0230] Both healthy and CVH mice were used to determine the effects of chronic colonic hypersensitivity on bladder contraction and bladder afferent neural pathways, as well as the effects of chronic daily administration of linaclotide (oral gavage; 3 μg / kg / day) for 2 weeks. For these studies, individually housed mice randomly assigned to each experimental group were used.
[0231] Ex vivo afferent nerve recordings Data are expressed as mean with SEM, n is the number of animals. Data were analyzed using unpaired t-tests to determine significance when comparing single points or two-way analysis of variance (ANOVA) when comparing between experimental groups throughout the ramp distention or exogenous agonist protocol. Differences were considered significant at P<0.05. Mechanosensory responses correspond to action potential discharges expressed as spikes / sec at a given pressure. Muscle compliance was calculated by plotting intravesical pressure against intravesical volume, which is determined from the time it takes to distend to a particular pressure. Chemosensitive responses correspond to action potential discharges expressed as spikes / sec and intravesical pressure at 20-s intervals after agonist application, plotted over the duration of the response.
[0232] Total multi-fiber afferent activity of the nerve was quantified using Spike 2 software, which counts the number of action potentials above a preset threshold. Data are presented as mean ± SEM. n indicates the number of individual animals. Data were analyzed using Prism 5 software (GraphPad Data were analyzed using the Statistical Modeling Software (San Diego, CA, USA) using unpaired t tests or post hoc tests following two-way analysis of variance (ANOVA) where appropriate. * P < 0.05, ** P<0.01 and *** Differences were considered significant at a level of P < 0.001.
[0233] Patch clamp recording Action potentials were recorded in current clamp mode and rheobase, or the amount of injected current (pA) required to elicit an action potential was determined. The resting membrane potential was recorded as well as the number of action potentials in rheobase and 2×rheobase. Data were analyzed using Prism 5 software (GraphPad Software, San Diego, CA, USA) with unpaired t-tests or two-way analysis of variance (ANOVA) followed by post hoc tests, as appropriate. * P < 0.05, ** P<0.01 and *** Differences were considered significant at a level of P < 0.001.
[0234] CVH mice show significantly increased bladder afferent nerve responses to a ramp bladder distension protocol compared to healthy controls. There is no change in bladder compliance when comparing bladder responses from CVH and healthy CVH mice, which also show significantly higher bladder afferent nerve responses to carbachol, αβMe-ATP and capsaicin, but are not associated with changes in muscle contraction. Bladder-traced TL and LS DRG neurons from CVH mice show significantly reduced rheobase (amount of current required to reach an action potential) compared to healthy controls.
[0235] Chronic daily administration of linaclotide for 2 weeks significantly reduced bladder afferent responses to ramp distention in CVH mice compared to vehicle controls. CVH mice receiving linaclotide once daily by oral gavage for 2 weeks had significantly reduced afferent nerve activity over both the time course of ramp distention (Fig. 2A, P ≤ 0.001) and the peak afferent response to distention (Fig. 2B, P ≤ 0.05) compared to mice receiving vehicle once daily by oral gavage for 2 weeks. The effect of linaclotide was more evident at higher distention pressures (Fig. 2A). There was no change in compliance between vehicle and linaclotide groups (Fig. 2C).
[0236] Chronic daily administration of linaclotide for 2 weeks also significantly reduced the afferent and contractile responses to carbachol and αβMe-ATP, but only the afferent response to capsaicin. Figure 3 shows bladder afferent responses to: A, carbachol (1 μM) p ≦ 0.001, B, capsaicin (10 μM) p ≦ 0.01, C, αβMe-ATP (30 μM) p ≦ 0.001 (2-way ANOVA Bonferroni multiple comparison test) in CVH mice receiving once-daily oral gavage of vehicle (blank, n = 7) or linaclotide (gray, n = 7).
[0237] Chronic daily administration of linaclotide for 2 weeks reversed the rheobase reduction of bladder sensory neurons observed in CVH mice. Figure 4 shows electrophysiological properties of retrogradely traced bladder thoracic-lumbar (TL) DRG neurons from CVH mice receiving once-daily oral gavage of vehicle (n=27) or linaclotide (n=25). In A, linaclotide significantly enhances rheobase compared to the vehicle group (p=0.02); in B, linaclotide significantly reduces the number of action potentials at 2× rheobase compared to the vehicle group (p=0.02); in C, linaclotide has no effect on resting membrane potential compared to mice receiving vehicle gavage. Figure 5 shows the rheobase of retrogradely traced bladder thoracic-lumbar (TL) DRG neurons from healthy control mice (n=19), CVH mice (n=22), and CVH mice receiving once-daily oral gavage of vehicle (n=27) or linaclotide (n=25). The rheobase was significantly reduced in CVH mice, and this effect was reversed by oral gavage of linaclotide (p≦0.05, one-way ANOVA).
[0238] TNBS colitis not only induces substantial MPO activity in the colon, but also induces extensive damage to the colonic mucosa, edema, and mast cell infiltration compared to healthy controls at both days 3 and 7 after TNBS. In contrast, no changes in MPO activity were observed and no mucosal damage occurred in the bladder at these time points.
[0239] Induction of the CVH state by intracolonic administration of TNBS results in a significant increase in bladder afferents that excite in response to mechanical stretch and chemical stimulation and a reduction in the rheobase of DRG neurons that innervate the bladder. Notably, chronic oral administration of linaclotide (3 μg / kg / day) for 2 weeks can normalize these effects.
[0240] Oral treatment with linaclotide (3 μg / kg / day) for 2 weeks could significantly attenuate TNBS-induced bladder hyperactivity in CVH mice by reducing the number of action potentials in bladder afferents resulting from bladder distension and extrinsic purinergic, muscarinic and TRPV1 activation. Furthermore, linaclotide treatment could reverse the reduction in rheobase observed in retrogradely traced bladder DRG neurons from CVH mice.
[0241] Example 17 Efficacy in clinical trials The primary objective of this study was to compare the efficacy of IR and DR formulations of linaclotide compared with placebo in treating overactive bladder symptoms.
[0242] Selection Criteria Eligible patients are willing and able to accurately complete voiding diaries and questionnaires. Subjects have symptoms of overactive bladder (urinary frequency and urgency with or without urge incontinence) for ≥3 months. Subjects experience an average voiding frequency of ≥8 times per 24 hours during the 3-day voiding diary period. Subjects must experience at least 3 urgency episodes (grade 3 or 4) with or without incontinence during the 3-day voiding diary period.
[0243] Exclusion criteria The subject is breastfeeding, pregnant, intends to become pregnant or is of childbearing potential during the study, is sexually active and does not practice a reliable method of contraception. The subject has significant stress incontinence or mixed stress / urge incontinence where stress is the predominant factor. The subject has an indwelling catheter or practices intermittent self-catheterization. The subject has diabetic neuropathy. The subject has evidence of symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignancy of the pelvic organs. The subject is receiving non-pharmacological treatments including electrical stimulation therapy. The subject has severe hypertension. The subject has known or suspected hypersensitivity to tolterodine, other anticholinergics, YM178, other beta-adrenergic receptor (β-AR) agonists, or either lactose or other inactive ingredients. Subjects have been treated with any investigational drug or device within 30 days (within 90 days in the UK). Subjects have a mean daily total urine volume >3000mL recorded in a 3-day voiding diary period. Subjects have serum creatinine >150umol / L, aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) >2x upper limit of normal (ULN), or gamma glutamyltransferase (γ-GT) >3x ULN. Subjects have a clinically significant abnormal electrocardiogram (ECG).
[0244] Subjects who meet the above inclusion criteria and do not have any of the exclusion criteria will be selected. Subjects will be randomized into three treatment groups: placebo, linaclotide IR, or linaclotide DR. The dose of linaclotide IR is 290 μg, administered orally once daily. The dose of linaclotide DR is 300 μg, also administered orally once daily. Treatment will be for 12 weeks.
[0245] The primary efficacy parameter is the change from baseline to the end of treatment (last visit) in the mean number of incontinent episodes per 24 hours. The mean number of incontinent episodes (any incident leakage of urine) per day is derived from the number of incontinent episodes recorded by patients in voiding diaries for the 3 days prior to the baseline and week 12 visits. Least squares (LS) means are generated from an analysis of covariance (ANCOVA) model with treatment group, sex, and geographic region as fixed factors and baseline as a covariate.
[0246] Another primary efficacy parameter is the change from baseline to the end of treatment (last visit) in the mean number of micturitions per 24 hours. The mean number of micturitions per 24 hours is derived from the number of times a patient voids per day (excluding incontinent episodes) recorded by the patient in a voiding diary for the three days prior to the baseline and week 12 visits. LS means are generated from an analysis of covariance (ANCOVA) model with treatment group, sex, and geographic region as fixed factors and baseline as a covariate.
[0247] Secondary outcome measures may include one or more of the following: - Change from baseline to the last visit in the mean volume excreted per void, calculated from the volume of each void measured by the patient over 3 days prior to the baseline and week 12 visits and recorded in a voiding diary. - Change from baseline to week 4 in the mean number of incontinent episodes per 24 hours, derived from the number of incontinent episodes recorded by patients in a voiding diary for the 3 days prior to the baseline and week 4 visits. - Change from baseline to week 4 in the mean number of voids per 24 hours, calculated from the number of voids recorded by the patient in a voiding diary for the 3 days prior to the baseline and week 4 visits. - Change from baseline to weeks 8 and 12 in the mean number of incontinent episodes per 24 hours, derived from the number of incontinent episodes recorded by patients in a voiding diary for the 3 days prior to the baseline, week 8, and week 12 visits. - Change from baseline to weeks 8 and 12 in the mean number of urinations per 24 hours, calculated from the number of urinations recorded by the patient in a voiding diary for the 3 days prior to the baseline, week 8, and week 12 visits. -Changes from baseline to weeks 4, 8, and 12 in the mean volume excreted per micturition, calculated from the volume of each micturition measured by the patient over 3 days prior to the baseline and week 4, 8, and 12 visits and recorded in a voiding diary. Change from baseline to weeks 4, 8, 12 and last visit in the mean number of urgency incontinence episodes per 24 hours, derived from the number of urgency incontinence episodes classified by the patient as 3 or 4 in a 3-day voiding diary based on the patient's perception of the urgency intensity scale as follows: 0=no urgency; 1=mild urgency; 2=moderate urgency where urination could be postponed for a short time; whereas, 3=severe urgency where urination could not be postponed; 4=urge incontinence where urination occurs before reaching the toilet. Change from baseline to weeks 4, 8, 12 and last visit in the mean number of urgency episodes (grade 3 or 4) per 24 hours, derived from urgency episodes classified by the patient as 3 or 4 based on the patient's perception of the urgency intensity scale in a 3-day voiding diary: 0: no urgency; 1: mild urgency; 2: moderate urgency, voiding could be postponed briefly; 3: severe urgency, voiding could not be postponed; 4: urge incontinence, leakage before reaching the toilet. Change from baseline to weeks 4, 8, 12 and the last visit in mean level of urgency based on the average of patients' ratings of the degree of urgency associated with each voiding and / or incontinent episode according to the following 5-point classification scale in a 3-day voiding diary (Patient Perception of Urgency Intensity Scale): 0: no urgency; 1: mild urgency; 2: moderate urgency, where urination could be delayed for a short time; whereas 3: severe urgency, where urination could not be delayed; 4: urge incontinence, where urination occurs before reaching the toilet. Change from baseline to weeks 4, 8, 12 and final visit in the mean number of nocturnal polyuria episodes per 24 hours; nocturnal polyuria is defined as waking up at least once during the night to void. The mean number of times patients voided during sleep hours per day (excluding incontinent-only episodes) was derived from a 3-day patient voiding diary. Change from baseline to weeks 4, 8, 12, and the final visit in the mean number of pads used per 24 hours during the 3-day voiding diary period Percentage of participants with zero incontinence episodes during the 3 days prior to each visit, at weeks 4, 8, 12 and the final visit, derived from patient-recorded voiding diaries. Percentage of participants with ≥ 50% reduction in incontinence episodes at Week 4, Week 8, Week 12 and final visit (percentage of participants with at least a 50% reduction from baseline in the mean number of incontinence episodes per 24 hours during the 3 days prior to each visit, derived from patient voiding diaries). Change from baseline to weeks 4, 8, 12 and final visit in symptom bother scores (overactive bladder symptoms were assessed using the symptom bother scale of the Overactive Bladder Questionnaire. The symptom bother scale consists of eight questions that participants answer on a scale of 1 to 6. A total symptom bother score was calculated from the eight responses and then converted to a range of 0 to 100, with 100 being the worst severity. A negative range from baseline in symptom bother scores indicates improvement). Change from baseline to weeks 4, 8, 12 and the final visit in health-related quality of life (HRQL) total score, as assessed by the HRQL subscales (coping, worry, sleep and social interaction) of the Overactive Bladder Questionnaire (OABq). A HRQL total score was calculated by adding the four HRQL subscale scores and converted to a scale of 0 to 100. Higher scores indicate better quality of life. A positive range from baseline in HRQL score indicates improvement. Work Productivity and Activity Impairment (WPAI): Change from baseline to Week 12 and final visit in percent of work time lost. WPAI: Using the SHP questionnaire, assess the degree and severity of overactive bladder (OAB) symptoms that interfered with work productivity during the last 7 days. Percentage of work time lost is derived from the number of work hours lost due to OAB symptoms as a percentage of the total time that should have been worked. Higher percentages indicate more time lost. Negative range from baseline indicates improvement. Work Productivity and Activity Impairment (WPAI): Change from baseline to week 12 and to the final visit in percent impaired at work. Work Productivity and Activity Impairment (WPAI): Change in overall percent work impairment from baseline to week 12 and to the final visit. Work Productivity and Activity Impairment (WPAI): Change in percent activity impairment from baseline to week 12 and to the final visit. Change from baseline to last visit in European Quality of Life-5 Dimensions (EQ-5D) mobility score. The EQ-5D is an international standardized non-disease specific (i.e. general) instrument for describing and assessing health status. Participants are asked to indicate which of the following best describes their health status: Change in European Quality of Life-5 (EQ-5D) self-management score from baseline to the final visit Change from baseline to the last visit in the European Quality of Life-5 (EQ-5D) usual activities score Change from baseline to the final visit in the European Quality of Life-5 (EQ-5D) pain / discomfort score Change from baseline to final visit in European Quality of Life-5 (EQ-5D) anxiety / depression score Change in European Quality of Life-5 (EQ-5D) visual analogue scale (VAS) from baseline to weeks 4, 8, 12 and the final visit Change in Patient Perception of Bladder Status (PPBC) from baseline to week 12 and final visit · Change from baseline to week 12 and final visit in treatment satisfaction on visual analog scale (TS-VAS). The TS-VAS is a visual analog scale (VAS) that asks patients to rate their satisfaction with treatment by placing a vertical mark on a 10 cm line that displays endpoints from "no, not at all satisfied" (=0) on the left to "yes, completely satisfied" (=10) on the right. LS means are from an ANCOVA model with treatment group, sex, and geographic region as fixed factors and baseline as a covariate. Positive range from baseline indicates improvement. Change in number of non-study-related physician visits (the number of times patients visited the physician's office for their bladder condition during the 4 weeks prior to each study visit, excluding study visits) from baseline to Week 4, Week 8, Week 12, and the last visit. Percentage of participants with improvement in Patient Perception of Bladder Status (PPBC) at Week 12 and Final Visit. The PPBC scale is a global assessment tool that asks patients to rate their impression of their current bladder status on a 6-point scale: 1: "It doesn't cause me any problems at all"; 2: "It causes me some very minor problems"; 3: "It causes me some minor problems"; 4: "It causes me (some) moderate problems"; 5: "It causes me serious problems"; 6: "It causes me many serious problems". Improvement was defined as an improvement of at least 1 point from baseline to post-baseline in PPBC score, and a major improvement was defined as an improvement of at least 2 points from baseline to post-baseline.
[0248] Example 18 Alternative Linaclotide Tablet Preparations The delayed release tablets were prepared by first preparing the following core tablet ingredients: placebo base, linaclotide 1000 μg / 225 mg base, and pregranulated filler.
[0249] Granulation manufacturing process: Tablet ingredients were prepared essentially as described in Example 7 above, with minor modifications as described below. The placebo base described in Table 28 was used to provide core tablets with the ingredients listed in Table 27. A final pH of 2.25 was used for the placebo and active base granulations.
[0250] [Table 27]
[0251] Placebo vehicle preparation: Table 28 shows the formula for the placebo base granulation: [Table 28]
[0252] A placebo base formulation was prepared by first blending the ingredients in Table 29. [Table 29]
[0253] Weigh the mixing vessel and add 2200±5.0 g of treated water (instead of 2682.1±5.0 g) to the vessel.
[0254] Linaclotide base preparation (1000μg / 225mg): Table 30 shows the formulation for 1000 μg / 225 mg base granulation: [Table 30] The remaining 0.02% represents a linaclotide impurity.
[0255] A 1000 μg / 225 mg base granulation can be prepared by first blending the ingredients in Table 31. [Table 31]
[0256] Preparation of pre-granulated filler: Table 32 presents the formulation for the pregranulated filler. [Table 32]
[0257] The filler formulations were prepared by first blending the raw materials in Table 33. [Table 33]
[0258] Example 19 Effect of tablet formulation changes on stability and impurities To determine the effect of various ingredients on the stability of linaclotide, several different formulations containing various amounts of PVA, CaCl2, histidine, and CCS were prepared and tested for drug substance loss and / or the appearance of degradants. The formulations were prepared as shown in Table 34.
[0259] [Table 34]
[0260] As indicated above, the formulations contained high or low concentrations of PVA (1.49 or 0.99% w / w), histidine (1.49 or 0.37% w / w), CaCl2 (0.71 or 0.18% w / w) or CCS (4 or 0% w / w).
[0261] Uncoated core tablets of the above formulation were packaged in 60cc white HDPE bottles with 3g of silica gel desiccant, heat sealed with an inner foil liner and closed with a 33mm white polypropylene child resistant lid. The sealed bottles were placed in a chamber at 40°C and 75% relative humidity (RH). Samples were taken at various time intervals and quantified for the amount of linaclotide as well as for ketone and immidazolidinone degradation products as described, for example, in US 8,933,030, which is incorporated by reference in its entirety. Linaclotide and degradation products were quantified using HPLC as outlined in Tables 35 and 36, respectively, and compared to the T=0 sample (non-stressed control).
[0262] [Table 35]
[0263] [Table 36]
[0264] As shown in Figure 6, tablets containing lower concentrations of PVA [0.99% (w / w), formulations B, C, D, E, K] showed loss of linaclotide in samples placed under stress conditions for 1 or 2 months, whereas tablets containing higher concentrations of PVA [1.25% (w / w)-formulation J, or 1.49% (w / w)-F, G, H, I] showed less loss.
[0265] Similarly, certain formulations were found to result in increased ketone formation. As shown in Figure 7, tablets containing low levels of CaCl2 [0.18% (w / w), formulations B, D, F, H] or medium levels of CaCl2 [0.44% (w / w), formulation J] were shown to result in increased ketone breakdown products in samples placed under stress conditions for 1 or 2 months. In contrast, samples containing 0.71% (w / w) CaCl2 showed reduced ketone formation.
[0266] The histidine concentration was found to affect the amount of immdidazolidinone formed in the tablets (Figure 8). In this case, low concentrations of histidine (formulations B, C, F, & G) resulted in higher levels of this degradation product, whereas tablets containing medium levels of histidine [0.93% (w / w), formulation J] or high levels of histidine [1.49% (w / w), formulations D, E, H, I & K] resulted in reduced formation of this degradation product.
[0267] Finally, formulation I, also described in Example 17, was compared to earlier formulations for linaclotide stability. Figure 9 compares the stability of linaclotide in formulation I compared to formulation 64B.
[0268] Other embodiments The present invention should not be limited in scope by the specific embodiments described herein. Indeed, various modifications of the present invention in addition to the embodiments described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. Moreover, it should be understood that all values are approximate and are provided for illustrative purposes.
[0269] All patents, patent applications, publications, product descriptions, and protocols cited throughout this application are hereby incorporated by reference in their entirety for all purposes. In an embodiment of the present invention, for example, the following items are provided: (Item 1) 1. A delayed release composition comprising an enteric coated tablet, said tablet comprising: Linaclotide; Ca2+; Histidine; and Polyvinyl alcohol (PVA) Including, The linaclotide is present in the composition in an amount of 30 μg to 300 μg. The composition. (Item 2) 2. The composition of claim 1, wherein the linaclotide is present in an amount of 30 μg. (Item 3) 2. The composition of claim 1, wherein the linaclotide is present in an amount of 100 μg. (Item 4) 2. The composition of claim 1, wherein the linaclotide is present in an amount of 300 μg. (Item 5) 5. The composition according to any one of items 1 to 4, wherein the enteric coating comprises a methyl acrylate-methacrylic acid copolymer (e.g. Eudragit®). (Item 6) 6. The composition according to any one of items 1 to 5, wherein the enteric coating comprises Eudragit® S100, Eudragit® L100, or a Eudragit® S100 / Eudragit® L100 mixture. (Item 7) 7. The composition according to any one of items 1 to 6, further comprising an enteric coating and a protective polymeric film or subcoating. (Item 8) 8. The composition of claim 7, wherein the subcoating comprises Opadry II®. (Item 9) Item 1. A unit dosage form comprising the pharmaceutical composition according to item 1. (Item 10) A method for producing the composition according to any one of items 1 to 8, i) preparing a linaclotide base, a pregranulation filler, and a placebo base; and ii) Blend and compress the linaclotide base, pregranulation filler, and placebo base. To make tablets The method comprising: (Item 11) 11. The method of claim 10, wherein the pregranulated filler is prepared via wet granulation and dried prior to blending and compression into tablets. (Item 12) 12. The method according to claim 10 or 11, wherein the method further comprises applying a subcoat to the tablet. (Item 13) 13. The method of claim 12, wherein the subcoat comprises Opadry II®. (Item 14) 14. The method according to any one of items 10 to 13, wherein the method further comprises applying an enteric or functional coating to the tablet. (Item 15) 15. The method of claim 14, wherein the enteric or functional coating comprises Eudragit® S100, Eudragit® L100, or a Eudragit® S100 / Eudragit® L100 mixture. (Item 16) A composition prepared by the method according to any one of items 10 to 15. (Item 17) 17. A method for treating a gastrointestinal disorder, comprising administering to a patient in need of treatment a therapeutically effective amount of the composition according to any one of items 1 to 8 or 16. (Item 18) 18. The method of claim 17, wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome (IBS), constipation, functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, diverticulitis, visceral pain, abdominal pain, gastroparesis, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, ulcerative colitis, and inflammatory bowel disease. (Item 19) 18. The method of claim 17, wherein the gastrointestinal disorder is constipation. (Item 20) 20. The method of claim 19, wherein the constipation is chronic constipation, idiopathic constipation, chronic idiopathic constipation, constipation caused by postoperative ileus, or constipation caused by opiate use. (Item 21) 18. The method of claim 17, wherein the gastrointestinal disorder is irritable bowel syndrome (IBS). (Item 22) 22. The method of claim 21, wherein the irritable bowel syndrome is constipation-predominant irritable bowel syndrome (IBS-c), diarrhea-predominant irritable bowel syndrome (IBS-d) or mixed irritable bowel syndrome (IBS-m). (Item 23) 18. The method of claim 17, wherein the gastrointestinal disorder is dyspepsia. (Item 24) 18. The method of claim 17, wherein the gastrointestinal disorder is gastroparesis. (Item 25) 25. The method of claim 24, wherein the gastroparesis is idiopathic, diabetic or post-operative gastroparesis. (Item 26) 18. The method of claim 17, wherein the gastrointestinal disorder is chronic ileus pseudo-obstruction. (Item 27) 18. The method of claim 17, wherein the gastrointestinal disorder is Crohn's disease. (Item 28) 18. The method of claim 17, wherein the gastrointestinal disorder is ulcerative colitis. (Item 29) 18. The method of claim 17, wherein the gastrointestinal disorder is inflammatory bowel disease. (Item 30) 18. The method of claim 17, wherein the gastrointestinal disorder is visceral pain. (Item 31) 18. The method of claim 17, wherein the gastrointestinal disorder is diverticulitis. (Item 32) 18. The method of claim 17, wherein the gastrointestinal disorder is abdominal pain. (Item 33) 18. The method of claim 17, wherein the gastrointestinal disorder is a cancer selected from colorectal / regionally metastatic colorectal cancer, gastric cancer, intestinal polyps, cancer of the gastrointestinal tract, cancer or precancerous or metastatic growths of epithelial cells or polyps of colorectal tissue. (Item 34) 17. A method for treating or alleviating pain, comprising administering to a patient in need thereof a therapeutically effective amount of a composition according to any one of items 1 to 8 or 16. (Item 35) 35. The method of claim 34, wherein the pain is selected from visceral pain; diverticulitis pain; pelvic pain; abdominal pain; or pain associated with a gastrointestinal disorder, a sexually transmitted disease, a painful bladder syndrome, or interstitial cystitis. (Item 36) 35. The method of claim 34, wherein the pain is selected from general abdominal pain, diverticular disease, pain associated with irritable bowel syndrome (IBS), chronic or acute radiation rectal disease (also called radiation proctitis), rectal pain, chronic perianal pain, resolving anorectal pain, anal region pain, chronic anal fissure, postoperative anal region pain, overactive bladder syndrome, stress urinary incontinence, interstitial cystitis, bladder pain syndrome, cancer-related pain, pain associated with gastrointestinal neoplasms, general pelvic pain, endometriosis, testicular pain, chronic prostatitis, prostatic pain, vulvar pain, urethral syndrome, penile pain, perianal pain, and pain associated with ulcerative colitis, ulcerative proctitis, or Crohn's disease. (Item 37) 17. A method for treating overactive bladder syndrome, bladder hypersensitivity or colitis-induced bladder afferent hyperactivity, comprising administering to a patient in need of such treatment a therapeutically effective amount of the composition according to any one of items 1 to 8 or 16. (Item 38) 17. A method for increasing intestinal motility in a patient, comprising administering to said patient a pharmaceutical composition according to any one of items 1 to 8 or 16. (Item 39) 17. A method for increasing guanylate cyclase C (GC-C) receptor activity in a biological sample or organism, the method comprising contacting said biological sample or organism with a composition according to any one of items 1 to 8 or 16. (Item 40) A method for producing the composition according to any one of items 1 to 8, comprising: i) preparing an aqueous solution containing linaclotide, or a pharma- ceutical acceptable salt thereof; and ii) applying said aqueous solution to a pharma- ceutical acceptable carrier. The method comprising: (Item 41) 41. A composition prepared by the method according to item 40.
Claims
[Claim 1] The invention described in this specification.
Citation Information
Patent Citations
Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2
Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2
